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I. INTRODUCTION
Acquired Immune Deficiency Syndrome ("AIDS") is among the greatest
challenges to modem epidemiology.' As the number of diagnosed cases and
predicted future infections mounts,2 the need to stem the transmission of the
Human Immunodeficiency Virus ("IP")3 becomes an increasingly crucial
public health issue. Since scientists first diagnosed AIDS and began to
understand its viral source in the early 1980s, lawmakers and policymakers
1. The numbers of cases of lIlV infection and AIDS throughout the world are staggering. See
Jonathan Mann et al., Toward a New Health Strategy to Control the HIVAIDS Pandemic, 22 J.L.
MED. & ETHICS 41 (1994) (discussing estimates of the extent of the HrV/AIDS pandemic).
2. The Centers for Disease Control and Prevention ("CDC") have issued a status report stating
that one million Americans, or one out of every 250, was infected with HIV as of mid-1994. HIV
Infection andAIDS-A Status Report, in SURGEON GENERAL'S REPORT TO THE AMERICAN PUBLIC ON
HIV INFECTION AND AIDS 1,1 (1994). For further discussion of recent numbers of AIDS cases and
predicted rates of HIV infection, see Richard M. Selik et al., HIVInfection as Leading Cause of Death
Among YoungAdults in U.S. Cities and States, 269 JAMA 2991, modified, Correction, 270 JAMA 710
(1993); Ann Rochell, AIDS Deaths in U.S. Top 200,000: Next 14 Months to Claim at Least 130,000
More, ATL. J. & CONST., Oct. 29, 1993, at Al; AIDS Deaths to Mount More Slowly, WASH. TIMES,
Jan. 15, 1993, at A2; and AIDS is Top KillerAmong Young Men, N.Y. TIMES, Oct. 31, 1993, § 1 at 19.
3. HIV is the virus believed by most authorities to cause AIDS. See generally WHO's Primer on
AIDS, 111 PUB. HEALTH REP. 7 (1996). For a discussion of a contrarian perspective that HIV does not
cause AIDS, see William Booth, A Rebel Without a Cause of AIDS, 239 SCIENCE 1485 (1988),
available in LEXIS, News Library, Asapii file. The contrarian perspective loses credibility as protease
inhibitors of HIV replication achieve unprecedented success in the treatment of AIDS. For a discussion
of the success of protease inhibitors in treating HIV-infected populations, see Expert Discusses Impact
of Treatments on Healthcare, AIDS WKLY. PLUS, Mar. 18, 1996, at 11, available in Westlaw, HWD
Database.
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have sought responses to eliminate or retard the spread of HIV. As the quest
for a vaccination or a cure has proven frustratingly elusive,4 managing AIDS
in the short term has come to depend largely on measures that control its
contagion.5
Some measures focus on reducing the instance of voluntary, high-risk
activities, such as unsafe sexual practices6 and the sharing of hypodermic
needles.7 Other measures attempt to lower the risk of unavoidable activities,
such as blood transfusion.8 This Article focuses on the latter challenge-the
development of laws, regulations, and policies to reduce the presence of HIV
in the blood supply. Section II briefly discusses the problem of blood supply
purity throughout the world. Section III distinguishes liability-based
approaches from rule-based approaches to improving blood purity. Section
IV examines and analyzes various rule-based options. Section V summarizes
the recommendations made throughout the Article.
II. A GLOBAL PERSPECTIVE OF TRANSFUSION-ASSOCIATED HIV
TRANSMISSION
For several years following identification of the earliest cases of AIDS,9
health officials had little reliable information about the relationship between
blood transfusions and the transmission of the disease."l After health officials
4. See Lawrence K. Altman, Little Progress Seen in Effort to Crack AIDS Puzzle, N.Y. TIMES,
June 12, 1993, at 5.
5. See Steven R Salbu. HIV Home Testing and the FDA: The Case for Regulatory Restraint, 46
HASTINGS L.J. 403, 434-35 (1995) (discussing avoidance of HIV infection as the most promising
means of averting the suffering and death associated with AIDS).
6. In this regard, the use of condoms has been widely adopted as a measure against the spread of
HIV. David L. Chambers, Gay Men, AIDS, and the Code of the Condom, 29 HARV. C.R.-C.L. L. REV.
353, 353 (1994).
7. For a discussion of public policy solutions to HIV infection via needle sharing, see Steven R.
Salbu, Needle Exchange, HIV Transmission, and Illegal Drug Use: Informing Law and Public Policy
with Science and Rational Discourse, 33 HARV. J. ON LEGIS. 105 (1996).
8. As of May 31, 1993, approximately 5500 cases of transfusion-induced AIDS were reported
in the United States. Richard M. Selik et al., Demographic Differences in Cumulative Incidence Rates
of Transfusion-Associated Acquired Immunodeficiency Syndrome, 140 AM. J. EPIDEMIOLOGY 105, 106
(1994). In many developing countries, the incidence of transfusion-induced AIDS is far higher. See
infra notes 20-30 and accompanying text.
9. Scientists identified the first cases of AIDS-related Kaposi's sarcoma in 1979 and later
identified AIDS as the cause. See Steven R. Salbu, Regulation ofDrug Treatments for HIV and AIDS.
A Contractarian Model ofAccess, 11 YALE J. ON REG. 401,402 n.1 (1994).
10. A very early report on the topic of possible blood-borne transmission of AIDS was issued by
the CDC in December of 1982. Possible Transfusion-Associated Acquired Immune Deficiency
Syndrome (AIDS)-California, 31 MORBIDITY & MORTALITY WKLY. REP. 652 (1982). A 1983 joint
19961
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confirmed that the AIDS virus was blood-bome t but prior to the
development of HIV antibody testing procedures,' 2 transmission of HIV by
transfusion was a daunting problem. Without a means of testing for
contamination, blood supplies were vulnerable, and transfusion of blood from
anonymous sources was tantamount to Russian roulette.' 3 Products derived
from human blood, such as blood-clotting medicines for hemophiliacs, were
also highly susceptible to HIV contamination. 4 Because of widespread
contamination of blood factor concentrate prior to 1985, HIV infection rates
in the early years of the AIDS epidemic were higher among hemophiliacs
than among any other group."
While innovative products and processes of the future may eliminate
transmission of EIV by transfusion, 6 contraction of AIDS through exposure
statement made by the American Red Cross, the American Association of Blood Banks, and the
Council of Community Blood Centers, characterized the spread of AIDS by transfusion as possible but
unproven. David Stevens, Negligence Liability for Transfuision-Associated AIDS Transmission: An
Update and Proposal, 12 J. LEGAL MED. 221,222 (1991).
11. In 1984, scientists first verified that AIDS was caused by HIV, a blood-bome virus. See
Kirkendall v. Harbor Ins. Co., 698 F. Supp. 768, 772 (W.D. Ark. 1988); Kozup v. Georgetown Univ.,
663 F. Supp. 1048, 1052 (D.D.C. 1987), af/'d in part and vacated in part, 851 F.2d 437 (D.C. Cir.
1988). At that time, HIV was known as the human T-lymphotropic virus type lII (HTLV-lI). See
Kirkendall, 698 F. Supp. at 772; Kozup, 663 F. Supp. at 1052.
12. The first license to manufacture an HIV-antibody test kit in the United States was granted on
March 2, 1985, to Abbott Laboratories. Karen S. Lipton, Blood Donor Services and Liability Issues
Relating to Acquired Immune Deficiency Syndrome, 7 J. LEGAL MED. 131, 131 (1986). Further
approvals for other manufacturers, as well as a movement by blood banks to incorporate routine HIV-
antibody testing into their procedures, followed within a few weeks. Id.
13. Because of this threat, the practice of autologous transfusion-the stockpiling of one's own
blood in anticipation of surgery-has become a common hedge against the uncertainties of transfusion
from blood supplies derived from anonymous sources. See infra notes 323-41 and accompanying text.
Even though HIV-antibody testing has reduced the risk of contamination by transfusion, autologous
transfusion has remained a popular alternative. See Martin R. Howard et al., Regional Transfusion
Centre Preoperative Autologous Blood Donation Programme: The First Two Years, 305 BRIT. MED. J.
1470, 1470 (1992) (noting the recent increased interest in autologous blood donation as an alternative
to voluntary blood donation).
14. Nine thousand hemophiliacs purportedly contracted AIDS in this manner. David Dishneau,
Hemophiliacs Live with Deadly Irony, ROCKY MOUNTAIN NEWS, Mar. 5, 1995, at 13A. More recently,
clotting factor concentrates for hemophiliacs have been rendered safer through a series of processes
used to inactivate viral contaminants, including solvent detergent treatment, pasteurization, and dry
heat treatment. Duncan P. Thomas, Viral Contamination of Blood Products, 343 LANCET 1583, 1583
(1994).
15. See Ron J. Perey, Hemophiliacs, Transfiusions, and AIDS: Liability for AIDS Contracted by
Hemophiliacs and Others from Blood Factor Concentrate and Blood Transfitsions, 14 TRIAL DIPL. J.
137, 140 (1991).
16. See, e.g., Hemolink Phase II Trials to Begin in 1996, AIDS WKLY., Jan. 1, 1996, at 11
(reporting development of a red blood cell substitute that shows some promise of reducing or
eliminating transfusion-related transmission of HIM. But see Rhonda L. Rundle, Analyst Pans Blood.
https://openscholarship.wustl.edu/law_lawreview/vol74/iss4/2
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to blood products remains a serious problem in many parts of the world. 7 The
recent phenomenon of blood screening for HIV i8 has reduced, but not
eradicated, transfusion-associated infection. Credible estimates indicate that
HIV has been transmitted to about 3000 people in the United States through
exposure to blood or blood products since the adoption of blood screening
tests in 1985.1" In many other countries, the risk of infection by transfusion is
far greater. Risks are especially high in some developing nations2" where
Substitute Firms, DENVER POST, Dec. 11, 1995, at E3 (reporting one securities analyst's observation
that blood substitutes degrade quickly after transfusion, and that surgeons therefore may be reluctant to
use them).
17. See, e.g., Chris Bull & Scott R. Akin, Bloody Shame, THE ADVOCATE, Dec. 14, 1993, at 24,
25 illus. (noting known exposure of hemophiliacs to HIV through tainted blood supplies in Canada, the
United States, Colombia, Nigeria, Spain, Britain, Zaire, France, Switzerland, Italy, Kenya, Uganda,
Japan, and China); Steven Dickman, One Finger in the Romanian Dike, 345 NATURE 379, 379 (1990)
(documenting a massive infection of malnourished infants through microtransfusions employing
contaminated blood, needles, and syringes).
Most studies indicate extremely low probabilities that HIV-infected blood will pass present
screening processes and enter the U.S. blood supply. See, e.g., Michael P. Busch et al., Evaluation of
Screened Blood Donations For Human Immunodeficiency Virus Type I Infection by Culture and DNA
Amplification of Pooled Cells, 325 NEW ENG. J. MED. 1, 1 (1991) (indicating the probability that a
screened donor in San Francisco will be positive for HIV-1 to be 1 in 61,171). However, while blood
testing and other prophylactic procedures have reduced the risk that tainted blood will enter the U.S.
blood supply, the separation of donated blood into component parts can allow more than one person to
become exposed to a single contaminated donation. Kate Bohner, Blood Strategies, FORBES, Sept. 27,
1993, at 152, 152.
While findings suggest that transfusion-related IlV infections are extremely rare and well
controlled in the United States, important questions remain. Researchers need to examine which
components of current U.S. policy are responsible for impressive safety levels of the national blood
supply and which aspects may be superfluous and inefficient. Unnecessary procedures for ensuring
blood safety may waste scarce financial resources and result in the undue curtailment of blood supplies
through excessive screening.
18. The earliest blood screening tests for IV antibodies were implemented in 1985. See AIDS
Cases from Transfusions Give Rise to Suits, N.Y. TIMES, July 26, 1991, at B16. Canada, for example,
began screening its blood supply for HiV antibodies in 1985, several years after the first AIDS
diagnoses. Accordingly, a number of Canadian provinces are adopting or considering policies to
encourage the HIV testing of individuals who received blood transfusions between 1978 and 1985.
Rebecca Wigod, Blood Transfusions: HIV Testing Considered in B.C. as Ontario Takes Action,
VANCOUVER SUN, July 23, 1993, at C11, available in 1993 WL 7614212.
Likewise, the screening of blood for HIV antibodies in the United States began in 1985. Given an
average period often years from time of infection to the development of AIDS, the number of persons
potentially infected via transfusion during the 1970s and the first half of the 1980s is large. Laurie
Garrett, Young People andAIDS, NEWSDAY, Aug. 4, 1992, available in 1992 WL 7548591.
For a discussion of the different types of screening tests and how they function, see John C.
Petricciani & Jay S. Epstein, The Effects of the AIDS Epidemic on the Safety of the Nation's Blood
Supply, 103 PUB. HEALTH REP. 236, 238-240 (1988).
19. Michael Chapman, How Safe is the Blood Supply?, CONSUMERS' RES., Apr. 1994, at 10, 14-
15.
20. See, e.g., P. Binda ki Muaka et al., Malaria, Anaemia, and HIV-1 Transmission in Central
Washington University Open Scholarship
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adoption and use of blood screening processes often lag.2' It has been
estimated that as many as ninety percent of those infected with HIV reside in
developing nations today.22
In some countries, transfusion still accounts for as much as ten percent of
all HIV infections.23 One recent study reveals a poor understanding among
blood donors in India regarding how AIDS is transmitted.24 An uninformed
public cannot effectively screen itself from attempting ill-advised donations.
Ignorance may partially explain the high levels of HIV contamination in
India's blood supply in the early 1990s,25 which led the Indian government to
suspend domestic manufacture of blood products.26
Africa has been especially susceptible to problems associated with the
contamination of blood supplies.2 Because health care budgets can be
severely constrained in developing nations, some governments have been
unable to implement policies that effectively mandate consistent HIV testing
of blood donations.28 Moreover, the earliest HIV tests detected antibodies to
HIV-1 and not the African HIV-2 strain29 which had not arrived in the United
Africa, 346 LANCEr 1294, 1294 (1995) (noting that transfusion of 1IV is a serious concern in a
number of Central African countries, particularly in conjunction with the management of childhood
anemia in regions where malaria is holoendemic).
The situation in some developing countries is such that the European Community has proposed a
Council Regulation to implement a program to assist developing countries in their efforts to combat
AIDS. Commission Proposal for a Council Regulation (EC) on HIV/AIDS-Related Operations in
Developing Countries, 1995 O.J. (C252) 4, available in Westlaw, CELEX Database.
21. Delays in the consistent implementation of blood testing in developing countries are often a
function of economic limitations. More consistent implementation of blood testing in cash-constrained
countries may be fostered by the recent development of relatively inexpensive tests for HIV-I and
HIV-2. See HIV Test Saves Lives in the Developing World, AIDS WKLY., Dec. 11, 1995, available in
1995 WL 13702505 (discussing a dipstick test developed in Seattle, which permits HIV testing
without support of elaborate laboratory facilities, at a cost of fifty cents per test).
22. AIDS Now Challenging Every Aspect of Third World Development, Canada Newswire, Feb.
11, 1994, available in westlaw, CANWIREPLUS Database.
23. Sharon Kingman, The Cost of Clean Blood, NEW SCIENTIST, Sept. 5, 1992, at 20,20.
24. N. Choudhury et al., AIDS Awareness in Blood Donors in North India, 5 TRANSFUSION MED.
267 (1995).
25. See Peter Kandela, India: HIVBanks, 338 LANCET 436, 437 (1991) (citing estimates that as
much as 95% of donated blood in India remained unsafe).
26. Id.
27. Charles W. Hunt,Africa and AIDS: Dependent Development, Sexism, and Racism, MONTHLY
REv., Feb. 1988, at 10, 10.
28. See Kingman, supra note 23, at 24.
29. For a discussion of the HIV-2 strain of the AIDS virus, see Francois Clavel et al., Human
Immunodeficiency Virus Type 2 Infection Associated with AIDS in West Africa, 316 NEW ENG. J. MED.
1180 (1987).
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States until the late 1980s.3°
Blood contamination scandals have arisen periodically in Europe, Asia,
and North America.3 ' Levels of blood supply safety vary substantially from
one country to the next,32 and while transfusion-associated HIV infections are
declining in most industrialized nations,33 they continue to rise in others.
Often, blood contamination incidents are associated with the purported
negligent failure of officials to mandate or implement policies that ensure
consistent blood screening.
French government officials and advisors, for example, were criticized in
the late 1980s for a 1985 contaminated blood scandal34 that allegedly resulted
from a failure to implement blood testing and screening procedures soon after
they became available.35 While many of the facts associated with the
transfusion of contaminated blood in France over a decade ago remain to be
determined, current charges include the provision of HIV-infected clotting
factors to hemophiliacs despite the existence of heat-inactivated alternatives,
the rejection of existing U.S. blood screening processes pending the
availability of French tests, and the common use of blood donations from
prisoners despite knowledge of the relatively high risk of AIDS among prison
populations.36 To avert future incidents of this nature, the Commission of the
European Communities introduced a system of controls in 1995, intended to
guarantee the quality and safety of blood and blood products.37
30. See infra note 205 and accompanying text; see also Kathryn G. Lotfi, Note, Suppliers of
AIDS-Contaminated Blood Now Face Liability, 34 HOW. L.J. 183, 191 (1991). More recently, tests
have been developed to detect the presence of HIV-2 antibodies. These tests are mandated in the
United States by the Food and Drug Administration (FDA). Monica Revelle, Progress In Blood Supply
Safety, FDA CONSUMER, Apr. 1995, at 21, 24 sidebar"Testing Blood."
31. For an overview of recent incidents related to HIV-contamination of blood in some European
and North American countries, see Richard L. Worsnop, Blood Supply Safety, 4 CQ RESEARCHER 987,
997-99 (1994). For discussion of a recent blood scandal in Japan, see infra notes 40-45 and
accompanying text.
32. See S. Franceschi et al., Trends in Incidence of AIDS Associated with Transfusion of Blood
and Blood Products in Europe and the United States, 1985-93, 311 BRIT. MED. J. 1534, 1534-35 &
tbls. 1&2 (1995) (examination of bloodbome AIDS rates in fourteen European countries and the United
States).
33. Transfision-Associated AIDS Cases in U.S. and Most of Europe Declining, AIDS WKLY.,
Jan. 29, 1996, available in 1996 WL 2093074.
34. Of 3000 French hemophilia patients, at least 1200 were estimated to have been infected with
HIV as of 1991. Jean-Yves Nau, France: HIV and Blood Testing, 338 LANCET 809, 809 (1991).
35. For a discussion of the contaminated blood scandal in France, see Are There Tragedies
Without Villains?, 371 NATURE 543 (1994).
36. Declan Butler, Blood Scandal Raises Spectre of Dreyfus Case, 371 NATURE 548, 548 (1994).
37. Commission of the European Communities, Pub. Health Law 15.18, Medicinal Products
Derived from Human Blood or Plasma, available in LEXIS, World Library, Law File.
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Allegations of similar incidents arise periodically throughout the
industrialized world. Following initial inquiries in the early 1990s concerning
blood contamination in Canada,38 a high-level Red Cross official was
investigated for purported negligence in administering Canadian blood
donation and transfusion programs, which allegedly have been responsible for
thousands of new HIV infections.39 Likewise, critics have suggested that the
Japanese government has understated or ignored incidents of transfusion-
related HIV transmission." Such charges recently led the Japanese
government to issue a formal apology4 and to create a Ministry of Health and
Welfare team to investigate the government's response to AIDS information
in the early 1980s.42 The team's early findings suggest that the Japanese
government suppressed a 1983 Ministry of Health and Welfare report that
identified, among other things, the high risk of HIV contamination in blood
products used by hemophiliacs.43 Commentators contend that the failure of
Japanese authorities to respond quickly to the information in the 1983 report,
particularly regarding the need for heat treatment of some blood products,44
resulted in avoidable infections.45
Throughout the world, the risk of transfusion-related HIV transmission
remains a serious problem. The following Section briefly discusses the two
generic approaches that have been adopted to address this issue-liability-
based and rule-based approaches. The latter are the main focus of this Article
and are explained in detail in Section IV.
38. See Tom Fennell, Voice of the Victims: An Inquiry Reveals How the Blood System Failed,
MACLEAN'S, Sept. 19, 1994, at 28, available in 1994 WL 6706577.
39. International Red Cross Boss May Face Misconduct Charge in Canada, AGENCE FRANCE-
PRESSE, Jan. 29, 1996, available in Westlaw, EURONEWS Database. For a general discussion of
Canada's problems regarding blood transfusions, see Wayne Kondro, Canada: Blood Transfitsion
Inquiry, 341 LANCET 1465 (1993).
40. Lawmaker: Gov't Not Addressing AIDS Issue, MAINICHI DAILY NEWS, Feb. 1, 1996, at 12,
available in LEXIS, World Library, Mainws File.
41. Miho Yoshikawa, Japan Reports Change in Pattern of Contracting AIDS, Reuters North
American Wire, Jan. 31, 1996, available in LEXIS, News Library, Cumws File.
42. Health Minister Kan Announces HIV Infection Study Team, Japan Econ. Newswire, Jan. 22,
1996, available in Westlaw, JWIREPLUS Database.
43. Ministry Shelved Report on Risk of Transfusions in '83, MAINICHI DAILY NEWS, Feb. 24,
1996, at 12, available in LEXIS, World Library, Mainws File.
44. Whereas heat-treated products were sold in the United States as early as March 1983, the sale
of heat-treated products was not approved in Japan until July 1985. Thomas M. Burton, Baxter, Bayer
Join Japanese Settlement for Hemophiliacs Who Got AIDS Virus, WALL ST. J., Mar. 15, 1996, at B5
(citing information provided by Bob Hurley, president of the Japanese unit of Baxter Int'l, Inc.).
45. See Government Aware of HIV Infection Risk Via Blood Products, Japan Econ. Newswire,
Feb. 21, 1996, available in Westlaw, JWIREPLUS Database.
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III. LEGAL, REGULATORY, AND PUBLIC POLICY CHALLENGES OF
TRANSFUSION-ASSOCIATED HIV TRANSMISSION
Experts estimate that between ninety46 and ninety-five percent47 of persons
transfused with blood infected by lIV-1 become seropositive48 themselves as
a result. Susceptibility to transfused iIV may be even higher among some
classes of patients, such as cancer patients, whose immune systems are often
already compromised at the time of surgery.49 Accordingly, ensuring the
integrity of blood supplies plays a critical role in the containment of AIDSi 0
Furthermore, because blood frequently crosses international borders,"' the
consistent adoption of policies that protect blood supplies and respect human
rights52 will be crucial to any effective global AIDS prevention policy.
46. Elizabeth M. Donegan et al., Infection with Human Immunodeficiency Pirus Type I (HIV-1)
Among Recipients of Antibody-Positive Blood Donations, 113 ANNALS INTERNAL MED. 733, 737
(1990) (reporting a 90% incidence of infection following transfusion of HIV-contaminated blood).
47. See J.W. Ward et al., Correspondence, Transfusion AssociatedHIVInfection, 322 NEW ENG.
J. MED. 775 (1990); see also Declan Butler, Concern over "Invisible Problem" of HIV Blood in
Developing Countries, 369 NATURE 429, 429 (1994) ("Receiving a transfusion of HIY-contaminated
blood carries a roughly 95 percent risk of HIV infection....").
48. Seropositivity refers to blood test results indicating infection with HIV.
49. See Peggy Easton, Cancer Patients at Low Risk from Blood Transfusions, 87 J. NAT'L
CANCER INST. 250, 250 (1995).
50. Possible HIV contamination of blood supplies has caused concern at various times in many
countries. See, e.g., Bhupesh Mangla, India: Disquiet About AIDS Control, 340 LANCEr 1533 (1992)
(discussing blood safety policy in India in the wake of discovery of HIV antibodies in indigenously
produced blood products); Alan Cowell, 4 Germans Convicted of Selling HIV Blood, INT'L HERALD
TRIB., Dec. 2, 1995, available in LEXIS, News Library, Cumws File (reporting the criminal conviction
of three German executives and a German lab technician for knowing distribution of tainted blood);
Stephen Kinzer, German Official Denies Starting an AIDS Panic, N.Y. TIMES, Nov. 6, 1993, at 5
(documenting the alleged distribution of HIV-tainted blood at numerous health centers in Germany);
Alan Riding, France Approved Use of AIDS-Tainted Blood, N.Y. TIMES, Oct. 20, 1991, § 1, at 7
(citing an official report that charged the French government with authorizing transfusions of
contaminated blood); Marlise Simons, France Convicts 3 in Case of HI. V-Tainted Blood, N.Y.
TIMES, Oct. 24, 1992, at I (reporting the conviction of former health officials whose alleged
distribution of HIV-tainted blood purportedly caused the infection of over a thousand hemophiliacs).
51. For example, blood products not tested for HIV antibodies by a company in Germany were
exported to countries in Europe and the Middle East. Bull & Akin, supra note 17, at 24 illus.
52. Although human rights issues may not seem highly relevant to blood supply issues at first,
actions such as the 1990 FDA ban on blood donations from all Haitian immigrants have sparked
considerable ire among concerned groups and activists. See generally Janice Somerville, FDA Position
Banning Haitian Blood Donation Stirs Protest, AM. MED. NEWS, June 15, 1990, at 3, available in
Westlaw, HWD Database. The FDA ban was lifted shortly after it was adopted. Janice Somerville,
FDA Reverses Policy, Drops Ban on Haitian Blood Donors, AM. MED. NEWS, Dec. 28, 1990, at 2,
available in Westlaw, HWD Database; Safer Blood, Fairer Policy, N.Y. TIMES, Dec. 7, 1990, at A34.
More recently, furor arose among Ethiopian immigrants in Israel in response to allegations that
their blood donations were being destroyed because officials believed the donations bore a high risk of
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A. Liability-Based Approaches
Liability for the provision or transfusion of contaminated blood can help
to ensure a pure blood supply by encouraging safe, responsible behavior.5 3 In
the United States,54 such liability is usually grounded in negligence,"5 not
strict liability or warranty theory. A number of decisions in the early 1980s
protected blood banks from negligence liability, reasoning that because the
risk of transfusion-associated AIDS was not commonly understood at the
time, HIV transmission could not have been avoided through the exercise of
reasonable care.56 The Supreme Court of Colorado departed from this
position in United Blood Services v. Quintana,57 suggesting that blood banks
could be held liable for negligence prior to the development of HIV blood
tests if they failed to employ "'available and proven scientific safeguards' in
acquiring, preparing, or transferring human blood or its components for use in
medical treatment." 8
HIV infection. See generally AJ Congress Says Decision in Israel to Discard Ethiopian Blood
Donations Was Taken "In Good Faith " and Is Not Racist, but Method Used Was "An Appalling
Mistake", PR Newswire, Jan. 31, 1996, available in Westlaw, PRWIREPLUS Database; Patrick
Cockburn, Black Israelis Riot Over Insult to Their Blood, INDEPENDENT (London), Jan. 29, 1996, at 9,
available in Westlaw, 1NDEPNDNT Database; Judy Siegel, MDA Accuses TV of Inciting Ethiopians,
JERUSALEM POST, Feb. 1, 1996, available in 1996 WL 4068559.
53. The threat of liability creates an incentive for parties to exercise care in the processing,
handling, and distribution of blood and blood products.
54. Scholars in other nations also grapple with the appropriate sphere of liability for blood-
related injuries in the era of AIDS. See, e.g., Sanda Rodgers, The Canadian Blood Delivery System:
LiabilityforBloodRelated Injuries, 21 OTrAWA L. REv. 311 (1989).
55. Juries have recently held blood collection and distribution centers liable for negligence in
collecting and screening blood and blood products prior to the development of blood screening tests.
See, e.g., George James, Blood Center Liable in H.I.V.-Infected Transfusion, N.Y. TIMES, Dec. 20,
1995, at B1. Negligence applies most obviously to those instances in which professionals failed to
screen blood or were careless in executing screening procedures after 1985, when the technology for
blood screening became widely available. However, courts differ on whether negligence is a viable
claim in connection with blood transfusions given prior to the availability of blood screening
technologies. Compare Doe v. University Hosp. of the N.Y. Univ. Med. Ctr., 561 N.Y.S.2d 326, 328
(N.Y. Sup. Ct. 1990) (stating that negligence claims for acts committed in 1984 are not foreclosed by
the pre-1985 unavailability of blood screening technologies) with Doe v. University of Cincinnati, 538
N.E.2d 419, 425 (Ohio Ct. App. 1988) (denying request of plaintiff for discovery because the
contaminated blood in question was donated prior to the development of tests for HIV antibodies). For
a general discussion of transfusion-related negligence, see Roger Parloff, Tainted Tort, AM. LAW.,
Sept. 1992, at76.
56. See, e.g., McKee v. Miles Lab., Inc., 675 Supp. 1060, 1063-64 (E.D. Ky. 1987), ajrd sub
nom., McKee v. Cutter Lab., Inc., 866 F.2d 219 (6th Cir. 1989).
57. 827 P.2d 509 (Colo. 1992).
58. Id. at 523 (discussing COLO. REV. STAT. ANN. § 13-22-104(1) (West 1989)). For a detailed
discussion of the case, see Jessamine R. Talavera, Quintana v. United Blood Services: Examining
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Strict liability and warranty actions have been less successful. 9 Most
states define the distribution of blood and blood components as a provision of
services rather than a sale of products,' effectively removing them from the
scope of strict liability and warranty actions,6 particularly when the provider
is a hospital.62 This majority approach has been codified in many states
through "blood shield statutes" that expressly label the provision of blood as a
service, exempt blood donations fiom strict liability, or both.63
Industry Practice in Transfusion-Related AIDS Cases, 2 CORNELL J.L. & PUB. POL'Y 475,477 (1993).
59. See, e.g., Kozup v. Georgetown Univ., 663 F. Supp. 1048, 1058-60 (D.D.C. 1987) (granting
summary judgment to hospital and blood bank in regard to warranty and strict liability claims),
vacated in part on other grounds, 851 F.2d 437 (D.C. Cir. 1988); Howell v. Spokane & Inland Empire
Blood Bank, 785 P.2d 815, 821-22 (Wash. 1990) (en bane) (declining to extend strict liability to the
collection and distribution of blood and blood products).
60. This characterization has been challenged by critics who contend that the conveyance of
products like clotting agents for home storage and self-administration more closely resembles a sale
than the provision of a service. See, e.g., J.M. Bielan, Bad Blood: What is a Blood Bank's Duty to
Prevent the Spread ofAIDS?. CAL. LAW., Apr. 1985, at 28, 31 (citing the reasoning of one lawyer who
has represented plaintiffs in litigation against blood banks).
61. Lipton, supra note 12, at 135-36. The statutory definition of blood as a "service" and not a
product has essentially enhanced the protection blood banks receive under their liability insurance
policies. See American Red Cross v. Travelers Indem. Co. of R.I., 816 F. Supp. 755 (D.D.C. 1993). By
relying on the statutory definition of blood rather than the contractual definition of "product! found in
the insurance policy, the Red Cross court effectively brought the liability within the scope of the
policy. Id. at 759. Furthermore, the Red Cross court defined each decision "to screen the donor ... to
test the blood, ... [or] to provide warnings" as a separate occurrence under the policy. Id. at 761. This
application of the policy's occurrence definition greatly increased the total insurance coverage
available to the Red Cross under the policy because "each act of distribution of contaminated blood
constitutes an 'occurrence' for purposes of applying the $1 million occurrence limit." Id.
62. See Perlmutter v. Beth David Hosp., 123 N.E.2d 792, 793-96 (N.Y. 1954) (establishing the
doctrine that a hospital's provision of blood is part of a service contract rather than a sales contract
with patients).
63. See ALA. CODE § 7-2-314(4) (1993); ALASKA STAT. § 45.02.316(e) (1994); ARIZ. REv.
STAT. ANN. §§ 32-1481, 36-1151 (1993); ARK. CODE ANN. § 20-9-802 (Michie 1991); CAL. HEALTH
& SAFETY CODE § 1606 (West 1990); COLO. REv. STAT. ANN. § 13-22-104(2) (West 1989); CONN.
GEN. STAT. ANN. § 19a-280 (West 1986); DEL. CODE ANN. tit. 6, § 2-316(5) (1993); FLA. STAT. ANN.
§ 672.316(5), (6) (West 1993); GA. CODE ANN. § 51-1-28 (1982); HAW. REV. STAT. § 327-51 (1985);
IDAHO CODE § 39-3702 (1993); 745 ILL. COMP. STAT. ANN. 4012-2 (West 1993); IND. CODE ANN.
§ 16-8-7-2(a) (West 1992); KAN. STAT. ANN. § 65-3701 (1992); Ky. REV. STAT. ANN. § 139.125
(Michie 1991); LA. REV. STAT. ANN. § 9:2797 (West 1991); ME. REV. STAT. ANN. tit. 11, § 2-108
(West 1995); MD. CODE ANN. CTS. & JUD. PROC. § 5-373 (1995); MASS. GEN. LAWS ANN. ch. 106,
§ 2-316(5) (West 1990); MICH. COMP. LAWS ANN. § 333.9121(2),(3) (West 1992); MISS. CODE ANN.
§ 41-41-1 (1993); MO. ANN. STAT. § 431.069 (Vernon 1992); MONT. CODE ANN. §§ 50-33-102 to -
104 (1995); NEB. REV. STAT. § 71-4001 (1990); NEV. REV. STAT. § 460.010 (1995); N.H. REv. STAT.
ANN. § 507:8-b (1983); N.M. STAT. ANN. § 24-10-5 (Michie 1994); N.D. CENT. CODE § 43-17-40
(1993); OHIO REV. CODE ANN. § 2108.11 (Baldwin 1993); OR. REV. STAT. § 97.968 (1995); S.C.
CODE ANN. § 44-43-10 (Law. Co-op. 1985); S.D. CODIFIED LAWS ANN. § 57A-2-315.1 (1988); TENN.
CODE ANN. § 47-2-316(5) (1992); TEX. Civ. PRAC. & REM. CODE ANN. § 77.003(a) (West 1986);
UTAH CODE ANN. § 26-31-1 (1995); VA. CODE ANN. § 32.1-297 (Michie 1992); WASH. REV. CODE
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While blood shield statutes historically have provided broad protection
against strict liability to blood providers, some signals suggest a movement
towards more expansive accountability.' For example, the Indiana Court of
Appeals has recently held that the state's blood shield statute protects only
blood banks and hospitals, not manufacturers of blood products." The ruling
is the first to deny pharmaceutical companies protection under a blood shield
statute.' Whether it represents a movement towards greater transfusion-
related liability in the future remains to be seen. Likewise, Federal Drug
Administration ("FDA") Commissioner David Kessler's assertion that blood
banks should be held to similar standards as private pharmaceutical
companies' suggests that a wider array of institutions, both public and
private, may be held accountable for the transfusion of tainted blood in the
future. Nations throughout the world are grappling with these same issues,
developing policies that will determine the appropriate bases of liability with
respect to the transfusion of HIV.68
B. Rule-Based Approaches
Rule-based means of protecting the public from blood-borne HIV
contamination are the focus of this Article. Statutes, regulations, and
institutional policies aimed at protecting the blood supply are all rule-based
approaches, reflecting an attempt to thwart HIV contamination by applying
mandatory, standardized practices and procedures to the processing and
handling of blood.69 Whereas liability-based approaches seek to discourage
ANN. § 70.54.120 (West 1992); WIS. STAT. ANN. § 146.31(2) (vest 1989); WYO. STAT. § 34.1-2-
316(c)(iv) (Michie 1991).
64. For arguments in favor of enhanced liability for impure blood products, including the
expansion of strict liability, see Michael J. Miller, Note, Strict Liability, Negligence and the Standard
of Care for Transfision-Transmitted Disease, 36 ARIZ. L. REV. 473 (1994).
65. See JKB, Sr. v. Armour Pharm. Co., 660 N.E.2d 602,604-06 (Ind. Ct. App. 1996).
For a discussion of the arguments for excluding manufacturers of blood products from strict
liability immunity, see Pamela T. Westfall, Note, Hepatitis, AIDS and the Blood Product Exemption
from Strict Products Liability in California: A Reassessment, 37 HASTINGS L.J. 1101 (1986).
66. Blood Shield Lmv Does Not Insulate Factor VIII Maker from Liability Suit, Health Care
Daily (BNA), Feb. 2, 1996, available in LEXIS, Bna Library, Bnahcd file.
67. See Philip . Hilts, F.D.A. Seeks Tighter Rules on Safety ofBlood Supply, N.Y. TIMES, July 2,
1993, at All (quoting FDA Commissioner).
68. See, e.g., M.P. Bastianon, Aids and the Blood Bank- The Argument for Strict Liability
Exemption, 11 U. TASMANIA L. REv. 191 (1992) (discussing bases of liability for the transfusion of
HIV under Australian law).
69. A good example of a regulatory approach towards ensuring the purity of the blood supply is
the FDA's five "layers of safeguards," which consist of donor screening, donor lists, blood testing,
(VOL. 74:913
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risky or negligent practices through the threat of punishment subsequent to
infraction, rule-based approaches establish barriers to eliminate opportunities
for contamination. The adoption of statutes, regulations, and policies that set
standards to prevent blood contamination will likely expand in the future,
given the threat of government liability for transfusion-related infections.
70
In the United States, rule-based approaches have yielded remarkable
improvements in the safety of blood transfusions.7' These improvements are
the result of a multitiered strategy that employs purportedly mutually
reinforcing policies72 to protect blood from exposure to contaminants and
individuals from exposure to contaminated blood. Many of these policies
have been adopted in various combinations in other parts of the world as well.
Donor interviewing and donor self-deferral are two similar, front-end
methods73 of screening out risky donations.74 In donor interviews, potential
donors are questioned to determine whether they fall within high-risk
categories and should therefore be prohibited from making donations. Under
self-deferral programs, officials inform prospective donors of the
qualifications to donate. Donors are required to disqualify themselves if they
fail to meet all qualifications. 75 The United States has also adopted an all-
volunteer blood donor policy,76 reasoning that sellers of blood face a conflict
of interest which encourages them to lie during the interview.77 After
quarantine of untested blood, and investigation of problems related to the processing of blood and
blood products. See generally Revelle, supra note 30, at 22-24.
70. For example, the province of Ontario, Canada, was sued in 1992 in regard to transfusion-
related infections. See Tony Wong, Ontario Faces 50 Lawsuits Over AIDS-Tainted Blood, TORONTO
STAR, Mar. 18, 1992, at F8.
71. The incidence of transfusion-related contraction of hepatitis, for instance, has declined from
approximately 30% three decades ago to approximately 1% today. Bradford W. Stone, How FDA
Safeguards the Blood Supply, FDA CONSUMER, June 1991, at 13, 15. Likewise, the risk of being
infected with HIV through a transfusion in the United States has fallen from approximately 0.04%
before screening was available, to around 0.0004% subsequent to the implementation of routine
screening. Worsnop, supra note 31, at 988.
72. Although the purported mutual reinforcement of policies is the ideal, it may not always be the
reality. A crucial question in assessing the effectiveness of the multitiered strategy focuses on the
marginal contributions of each tier. As discussed in Section IV, infra, some tiers add negligible
effectiveness to the overall strategy at a substantial and unjustifiable cost.
73. The term "front-end method" refers to means of preventing risky blood donations from ever
being made. In contrast, a "back-end method" discourages risky or infected donations that have
already been made from being incorporated into public blood supplies.
74. See infra Section IV.C.
75. Obviously, donor interviewing and donor self-deferral can be combined at a single site for
mutual reinforcement
76. See infra Section IV.B.
77. U.S. Blood Supply Safe, Researchers Say, Reuters North American Wire, Nov. 6, 1994,
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voluntary donors have been qualified on the basis of interview responses and
self-deferral procedures, their donations are tested, and if contaminated with
lIV, quarantined from the blood supply.7"
To reinforce these policies, the United States and other countries have
promulgated regulations governing the operating procedures of organizations
that collect or distribute blood or blood products.79 Some local authorities, as
well as national organizations like the American Red Cross, maintain
registries listing the names of persons who have attempted to donate blood,
but tested seropositive at the time of the attempted donation."0 The registries
are used to disqualify rejected donors who try to make subsequent
donations."1 Registration processes have also been used to trace donations
originally believed to be uninfected but later found to be contaminated. 2
Finally, some commentators have encouraged autologous transfusion, 3
directed transfusion, 4 and so-called "bloodless surgery" 5 as means of
averting new HIV infections.8 6
Despite these potential safeguards, individuals continue to become
infected with HIV through the transfusion of blood and the use of blood
products.8 7 Even in the United States, where safety of the blood supply has
improved dramatically, critics suggest that the risk of transfusion-related HIV
infection remains a serious problem.8 Nonetheless, responsible policies must
account for both the costs and the benefits of potential marginal
available in LEXIS, News Library, Allnws File.
78. See Elisabeth Rosenthal, Blood Banks Vigilant But Vouch for Safety, N.Y. TIMES, July 27,
1992, at B2 (writing that "[tihe safety of the blood supply is maintained by questioning potential
donors... as well as by testing donated blood").
79. See, e.g., 1989 O.J. (L 181) 44 (procedures for screening blood supplies in European
Community), available in Westlaw, CELEX Database; 1991 OJ. (L 175) 26 (establishing "Europe
Against AIDS Program," which includes provision for ensuring safety of blood transfusions),
available in Westlaw, CELEX Database; infra Section IV.D.
80. See infra Section WV.E.
81. See infra notes 276-78 and accompanying text
82. See infra Section W.F.
83. See infra notes 323-41 and accompanying text
84. See infra notes 342-53 and accompanying text.
85. See infra notes 354-64 and accompanying text.
86. See infra Section WV.G.
87. See Revelle, supra note 30, at 22 (noting that despite improvements in protecting the blood
supply, some risk of HIV infection still exists).
88. For point-counterpoint arguments regarding the safety of the U.S. blood supply today, see At
Issue: Is the Blood Supply in the United States Safe?, 4 CQ RESEARCHER 1001 (1994) (summarizing
the conflicting positions of the American Red Cross and Michael Chapman, former associate editor of
a consumer research publication).
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improvements to the integrity of blood supplies. Whereas some of the policies
examined in this Article are fairly uncontroversial, others have been the
subject of heated debate. The following Section examines and assesses the
most significant rle-based approaches.
IV. AN ANALYSIS OF BLOOD POLICY OPTIONS
This Section examines the most promising rle-based approaches to
reducing the incidence of transfusion-associated lIlV transmission. The
proposed policies are examined in subsequent subsections and include (A)
mandatory testing of donated blood and rejection of contaminated donations;
(B) prohibition of the sale of blood through a mandatory all-volunteer policy;
(C) predonation questioning and disqualification of donations from persons in
high-risk categories; (D) regulations requiring improvements in information
transmission, operating procedures, and the maintenance of blood supplies;
(E) development and maintenance of information registries; (F) ex post facto
procedures to trace recipients of blood identified as high-risk or tainted
subsequent to transfusion; and (G) encouragement of autologous transfusion,
directed donation, and bloodless surgery.
A. Mandatory Testing ofDonated Blood and Rejection of Contaminated
Donations
Among the less controversial regulatory measures is mandatory post-
collection screening prior to incorporating donations into the public blood
supply. 9 Since the first widely respected blood test for HIV antibodies
became available in 1985, 0 the screening of specimens has become a fairly
89. While the concept of post-collection screening of blood donations is not controversial, the
degree of rigor associated with blood testing has been the subject of some debate. Because existing
tests serve as highly effective screens when properly and consistently administered, supplemental tests
often yield negligible benefits at substantial cost. For a specific example of this problem, see infra
notes 121-34 and accompanying text.
While the costs of blood screening procedures vary, the literature clearly suggests that some form
of blood screening is cost effective. See, e.g., Richard S. Eisenstaedt & Thomas E. Getzen, Screening
Blood Donors for Human Immunodeficiency irus Antibody: Cost-Benefit Analysis, 78 AM. J. PuB.
HEALTH 450, 453 (1988) (concluding that "current testing procedures generate net economic benefits
in aggregate").
90. See supra note 12. Unfortunately, transfusion-associated iV contamination was not
uncommon prior to the availability of reliable blood screening technology. According to National
Hemophilia Foundation estimates, approximately 10,000 people in the United States were infected
from blood-clotting products prior to the implementation of safeguards. Larry MacIntyre,
19961
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common worldwide practice.9 After routine blood donation testing was
implemented in the United States, the risk of being infected with HIV through
a transfusion fell from approximately 1 in 2500 to around 1 in 225,000.92 In
addition to protecting blood supplies, donor testing can also provide unique
kinds of data that can improve our understanding of how HIV is transmitted.93
Given the high incidence of HIV infection throughout many parts of the
world, failure to implement specimen testing and screening procedures would
be disastrous.94 The only factors that might reduce the desirability of a
Pharmaceuticals Lose Lawsuit Protection, INDIANAPOLIS STAR, Jan. 25, 1996, available in 1996 WL
3119163.
91. The screening of blood donations has been more effectively implemented in some countries
than in others. For example, transfusion-related infections remain alarmingly high in communist or
formerly communist countries, where officials have been slow to adopt fundamental safety procedures
that are standard in most industrialized nations. See, e.g., Risks of AIDS Largely Ignored in Romania,
AIDS WKLY., Jan. 8, 1996, available in 1996 WL2092936.
Transfusion of HIV-contaminated blood is also relatively common in some developing countries
that have access to, and purportedly employ, blood screening technologies. The failure of
pretransfusion testing to reduce the transmission of HIV effectively in these countries has been
attributed to the inconsistency of testing, as well as high levels of donor seropositivity. Accordingly,
transfusion remains the source of between 5% and 10% of all HIV infections worldwide. Butler, supra
note 47, at 429.
92. Worsnop, supra note 31, at 988.
93. Self-screening and disqualification criteria render blood bank donors a uniquely valuable
population from whom investigators can discover previously unidentified modes of HIV transmission.
See Lyle R. Petersen et al., Methodologic Approaches to Surveillance of HIV Infection Among Blood
Donors, 105 PUB. HEALTH REP. 153, 153 (1990). Assuming that disqualification based on behavioral
patterns or donor status is reasonably effective, blood donations given by those originally qualified to
donate but later discovered to be infected will provide researchers with a pool of persons whose
infection cannot be easily or immediately explained by known causes. See id. at 155-56. While some
cases will reflect error in donor self-assessment, personnel's assessment of donors, or false reporting,
other cases may reflect high-risk behaviors that have yet to be identified as common means of
transmitting HIV. See id. at 153-56. Presuming ethical issues regarding donor confidentiality are
addressed carefully and conscientiously, scientists can and should study disqualified donor groups to
understand more about how HIV is spread. The resulting findings have the potential to inform the
public further about risky behaviors and to enable blood collection centers to establish more accurate
criteria for donor self-deferral. See id. at 157.
94. The risk of not screening blood donations obviously increases proportionately with the
prevalence of HIV infection in any given donor population. The prevalence of HIV infection and the
attendant risk from failing to screen blood donations differ considerably by region. For example, the
World Health Organization estimates that at least five million African adults have been infected with
HIV as of 1991, and health care workers have reported that AIDS cases have doubled among certain
populations in Africa every eight months. Louis W. Sullivan, A Presidential Health Mission to Afrlca,
106 PuB. HEALTH REP. 105, 108-09 (1991). These disproportionately high infection rates in Africa
vary by geographic area. The proportion of the population believed to carry the AIDS virus in South
Africa has recently been estimated at 2.1%. In contrast, infection rates in urban areas of Zimbabwe,
Zambia, and Uganda have been estimated at between 20% and 30%. Hugh Pope, AIDS Set to Engulf
South Afica, INDEPENDENT (London), Mar. 8, 1995, at International 13 available in Westlaw,
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particular specimen screening procedure are inaccuracy or prohibitive cost.
As is demonstrated in the following subsections, the kinds of blood tests that
are routinely employed in the United States today-ELISA and Western
Blot-are both accurate95 and reasonably cost effective.96 These tests are
discussed in Section IV.A. 1. In addition, the FDA is requiring blood banks to
administer supplemental HIV-antigen tests beginning in 1996.97 As we shall
see in Section IV.A.2, these tests do not withstand a reasonable social cost-
benefit analysis. Section IV.A.3 discusses an important post-screening issue
that various countries address in divergent ways: whether donors whose
specimens test seropositive should be informed of their lIV status.
1. ELISA and Western Blot Blood Tests
The FDA first approved an HlV-antibody blood test in early 1985."s The
test most commonly used to detect HIV antibodies in blood donations is
called ELISA, an acronym for "enzyme-linked immunosorbent assay."99
INDEPNDNT Database.
In the United States, concentrated drug use has contributed to disproportionately high infection
rates in some inner-city neighborhoods. See MARY ELLEN HOMBS, AIDS CRISIS IN AMERICA: A
REFERENCE HANDBOOK 11 (1992) ("Epidemiological evidence has shown that the geographic
concentration of drug use in certain parts of the inner city results in geographic concentration of HIV
and very high rates of infection in the population of these neighborhoods."). Without blood testing and
screening, the proportion of the blood supply containing HIV in such areas could approach the
frighteningly high infection rates of the donor populations. While measures like the refusal to accept
donations from persons in high-risk classes could reduce the proportion of donated blood infected with
HIV, such measures would likely be of limited effectiveness without blood testing and screening due
to such constraints as faulty donor reporting.
95. See infra notes 100-01.
96. See infra notes 104-05 and accompanying text.
97. See Memorandum from Kathryn C. Zoon, Ph.D., Director, Center for Biologics Evaluation
and Research, Public Health Service, FDA, to All Registered Blood and Plasma Establishments,
Recommendations for Donor Screening with a Licensed Test for HIV-1 Antigen 4 (Aug. 8, 1995),
available at (visited on Nov. 15, 1995) <http://www.fdq.govlcber/cberftp> [hereinafter Antigen
Memorandum]; see also New AIDS Screening Test Detects Virus Earlier; Now Available to Blood and
Plasma Collection Centers, PR Newswire, Mar. 14, 1996, available in Westlaw, PRWIREPLUS
Database; Sally Squires, Blood Banks Adopt Stricter AIDS Test, WASH. POST, Apr. 2, 1996, Health
Mag., at 6.
98. The test was developed by Abbott Laboratories. See Della De Lafuente, After 10 Yrs. Abbott
Still AIDS Test Leader, CHI. SUN-TIMES, Mar. 2, 1995, available in 1995 WL 6647044; see also supra
note 12. Abbott Laboratories has since developed and marketed four refined versions that incorporate
technological advances, yielding improved accuracy and reliability. Id.
99. After the development of blood ELISA tests, companies began experimenting to develop
saliva ELISA tests. In early 1995, the FDA approved a product called "OraSure," a saliva ELISA test
for HIV antibodies manufactured by Epitope Corporation. Statement on FDA Approval of AIDS Virus
Test System Based on Oral Fluid Samples, PR Newswire, Dec. 23, 1994, available in Westlaw,
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ELISA results, fairly reliable in their own right, can be confirmed using the
more specific, and more expensive, Western Blot test.100 In tandem with
Western Blot confirmation, ELISA yields high levels of diagnostic
accuracy.' While the Centers for Disease Control and Prevention ("CDC")
have recommended the use of Western Blot testing for the confirmation of
positive ELISA results,"02 critics contend that Western Blot confirmation is
expensive, laborious, subjective, and indeterminate. 3
Evidence suggests that mandating ELISA testing with Western Blot
confirmation is prudent. Professor Gregory Gelles has studied blood
screening costs and the numbers of transfusion-related HIV infections that are
directly averted as a result of ELISA and Western Blot confirmation."'4 He
estimates that the cost of preventing each direct infection ranges from
$36,300 to $128,833.°5 Even at the higher end, these costs are low compared
to the costs of failing to prevent an infection, which include (i) treating the
patient for life, (ii) the patient's pain and suffering, (iii) life-years lost to
PRWIREPLUS Database [hereinafter Statement on FDA Approval].
The potential use of saliva ELISA tests to screen prospective blood donors for HIV is
controversial. Although it approved the saliva ELISA test, the FDA contends that OmSure is less
accurate than the blood-based ELISA tests currently in use. According to the FDA, OraSure fails to
detect one or two infected persons for every hundred infected persons tested and gives false positive
diagnoses of approximately two people for every hundred uninfected persons tested. Joyce Price, FDA
Approves Saliva Test for HIV' but Agency, Maker Differ a Little on OraSure's Accuracy, WASH,
TEs, Dec. 24, 1994, available in 1994 WL 10986511; Statement on FDA Approval, supra. Epitope
Corporation contends that the difference is more minute-99.6% accuracy for blood ELISA tests
versus 99.2% accuracy for Orasure. Price, supra, at Al. For further study of the saliva ELISA test's
reliability, see A.J. Hunt et al., The Testing of Saliva Samples for HIT'-) Antibodies: Reliability in a
Non-Clinic Setting, 69 GENITOURINARY MED. 29 (Feb. 1993).
Under present FDA policy, OraSure has been approved for professional diagnostic use, but not for
the screening of blood donors. Statement on FDA Approval, supra.
100. Robert N. Husson et al., Diagnosis of Human Immunodeficiency Virus Infection in Infants
and Children, 86 PEDIATRICS 1, 3 (1990). For a discussion of the sensitivity and specificity of both
tests, see Evelyne T. Lennette et al., Indirect Immunofluorescence Assay for Antibodies to Human
Immunodeficiency Virus, 25 J. CLINICAL MICROBIOLOGY 199 (1987).
101. See P. Kimmig, Sensitivitat und Spezifltdt von Untersuchungsverfahren bei HIT' [Sensitivity
and Specificity of HIV Tests], 52 DAS OFFENTLICHE GESUNDHEITSWESEN 419 (1990) (stating the
sensitivity of HIV blood tests to be approximately 99 to 100%, and the specificity to be I false positive
per 50,000 to 100,000).
102. CENTERS FOR DISEASE CONTROL, AIDS PROTOTYPE GUIDELINES (1988).
103. V. Soriano et al., Evaluacidn de diferentes criterios de interpretacidn del Western blot para
el diagndstico de la infeccidn por el virus de la inmunodeficiencia humana (Evaluation of Different
Criteria of Interpretation of the Western Blot for the Diagnosis of Infection by the Human
Immunodeficiency ints], 100 MEDICINA CLfNICA 561 (1993).
104. See Gregory M. Gelles, Costs and Benefits of HIV-1 Antibody Testing of Donated Blood, 12
J. POL'Y ANALYSIS & MGMT. 512 (1993).
105. Id. at520.
[VOL. 74:913
https://openscholarship.wustl.edu/law_lawreview/vol74/iss4/2
AIDS AND THE BLOOD SUPPLY
AIDS, and (iv) potential infection of others through the recipient of
unscreened blood.'06
Moreover, because of technological improvements in ELISA testing,
HV-antibody screening processes are becoming increasingly effective at
preserving the purity of the blood supply. Whereas experts estimated that
assays used in the late 1980s identified HIV antibodies an average of forty-
five days after infection, ,o7improved assays now detect recombinant, protein-
based HIV antibodies an average of twenty-five days after infection."8 In
effect, technological improvements have nearly halved estimates of the period
of "serolatency"---the span of time after infection but prior to the production
of antibodies, during which tests will yield false negative results." 9 Because
false negative results are a troublesome source of error that may permit
contaminated blood to enter the blood supply,"' the downward adjustment of
the window period suggests that ELISA testing and Western Blot
confirmation are becoming increasingly effective.
2. Antigen Testing
The difficult questions associated with mandatory testing of blood
donations concern the rigor with which specimens should be tested, rather
than whether they should be tested at all. Given that the development and
106. Screening of blood avoids this final cost in at least two ways. First, some prospective donors,
upon discovering through screening that they carry HV, will alter their behavior and avoid high-risk
contacts with other parties. Second, those whose transfusion with HIV-contaminated blood is averted
by screening avoid infection themselves, thereby eliminating the possibility of passing the virus on to
secondary parties. See id. at 521.
107. See generally L.R Petersen et al., Duration ofTimefrom Onset of Human Immunodeficiency
Virus Type I Infectiousness to Development ofDetectable Antibody, 34 TRANSFUSION 283 (1994).
108. See M.P. Busch et al., Time Course of Detection of Viral and Serologic Markers Preceding
Human Immunodeficiency Virus Type I Seroconversion: Implications for Screening of Blood and
Tissue Donors, 35 TRANSFUSION 91 (1995).
109. The period between HIV infection and the development of identifiable HIV antibodies is also
commonly referred to as the "window period."
110. Although the window period provides an opportunity for HIV-contaminated blood to enter
the public blood supply undetected by routine testing, the estimated incidence of such cases is
surprisingly infrequent. Recent CDC estimates suggest that one in 360,000 donations occurs during the
window period of antibody undetectability. Study Finds Risk of HIV Transmission Small, AIDS
WKLY., Jan. 15, 1996, available in 1995 WL 2092974. Nevertheless, the window period is considered
to be responsible for most cases of transfusion-associated lfIV transmission today. See Use of
Seroconversion Panels to Estimate the Reduction in the "Window" Period Between the Appearance of
Nucleic Acid and Serological Markers in HIV, HBV and HCV Infected Blood, AIDS WKLY., Dec. 18,
1995 (printing an abstract of a study by M. Manak et al., presented at a 1996 meeting of the Am. Ass'n
of Clinical Chemistry), available in 1995 WL 13702256.
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adoption of effective new blood screens has already raised the cost of
collecting and distributing blood substantially since the mid-1980s,"'
authorities must decide the point at which a new test's incremental protection
cannot justify its direct and indirect incremental costs.' The recent debate
over requiring supplemental antigen testing brings this discussion into focus.
Recently, for example, a panel from the National Institutes of Health
("NIH") reviewed a series of tests presently used to screen HIV, syphilis, and
hepatitis.' The findings suggest that a point exists where adding a new test
provides negligible screening benefits, by rendering enough false positive
results to cause blood banks to dump hundreds of thousands of units of
untainted blood.'14
False positives associated with supplemental screening can exacerbate
blood shortages at a time when blood donations are already down
significantly."5 In countries that operate under blood deficits, such as the
United States" 6 and Canada," 7 reductions in the blood supply can be both
costly and dangerous. The social cost of this waste depends upon a number of
factors, including the prevalence of false positive results from the
supplemental screening under consideration, the scarcity of blood supplies,
and the concomitant degree to which disposal of uninfected blood will affect
morbidity and mortality rates.
The trade-off between rigor in finding tainted blood and the increased
111. Whereas blood centers typically administered two tests on each donation sample in 1985,
they now administer eight tests. Robert Mullins, Blood Center Lookingfor a New Transfusion, BUS. J.-
MILWAUKEE, Feb. 3, 1996, available in 1996 WL 8800178.
112. Direct costs refer here to the laboratory bills that mount with each supplemental screening
test. Indirect costs refer to social costs, such as the loss of untainted blood due to error from each new
screening test that is administered. Sources of testing error include imperfections in a screening test's
ability to detect antibodies or antigens accurately, the inability of screening tests to detect the presence
of HIV antibodies during serolatency, the incidence of false positive test results, and human error in
administering all forms of safeguards against blood contamination. The more tests that are employed to
keep tainted blood from slipping through the cracks, the more opportunities there are for false positive
diagnoses, and the more good blood that will be discarded.
113. See Tina Adler, Debugging Blood: Protecting People from Tainted Blood, 147 Sci. NEWS,
92,92 (1995).
114. See id.; see also Elizabeth Corcoran, The Burden of Proof Donated Blood Runs a Costly
Gauntlet ofTests, SCI. AM., Apr. 1989, at 79, 79-80.
115. Blood donations in the United States are 6% lower than they were 10 years ago. Eric Lax,
Blood Ties: One Gift: Two Lives Forever Changed, LIFE, Mar. 1996, at 60, 65 sidebar "Donating
Blood: A Primer."
116. In 1989, the United States imported approximately 2% of its blood supply. Jeffrey
McCullough, The Nation's Changing Blood Supply System, 269 JAMA 2239, 2239 (1993).
117. Cf Wayne Kondro, Canada: Blood Self-Sufficiency, 340 LANCET 1341, 1341 (1992)
(discussing one strategy in Canada for achieving self-sufficiency in blood and blood products).
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likelihood of rejecting good blood will be unavoidable as long as error
remains associated with blood screening processes. The task for lawmakers
and policymakers is to determine the point at which the enhancements
provided by a new procedure are outweighed by (i) the social cost of the
incremental units of untainted blood discarded as a result of adopting the
procedure and (ii) the direct expense of administering the additional tests."'
The most prominent recent controversy over a proposed supplemental
screening test concerns antigen testing. Antigen testing's potential advantage
is its ability to detect the presence of antigens after infection faster than
ELISA can detect antibodies, thereby reducing both the period of serolatency
and the window of opportunity during which the virus will be undetectable." 9
The challenge to regulatory authorities has been to weigh the costs and
benefits of antigen testing, given the relative success of ELISA screening with
Western Blot confirmation.'2°
Investigators who have assessed the use of antigen testing to supplement
HIV-antibody tests have found the process ineffectual and expensive."' In a
comprehensive field study that tested hundreds of thousands of donors in a
variety of geopolitical settings, no donations found positive for antigens were
found negative for HIV-1 antibodies.' In other words, supplementing
existing antibody screens with antigen testing conferred no added diagnostic
value."2 Some medical researchers concede that antigen testing could
118. This balancing test applies to any new safeguards that lawmakers or policymakers consider
adding to existing protections, regardless of whether the safeguard being considered is a supplemental
screening test or another mechanism aimed at reducing transfusion-related HIV infections. For
example, researchers have recently assessed the marginal value of the solvent-detergent treatment of
plasma, a process in which plasma donations are treated rather than screened. See James P. AuBuchon
& John D. Birkmeyer, Safety and Cost-Effectiveness of Solvent-Detergent-Treated Plasma, 272 JAMA
1210 (1994). The investigators determined that although the treatment of plasma process may save
some life-years, its adoption is probably unjustifiable in terms of the marginal life-years saved and the
costs of implementation. Id. at 1212-13.
119. See Gelles, supra note 104, at 523.
120. See supra Section IV.A.1.
121. See Michael P. Busch et al., Screening of Selected Male Blood Donors for p24 Antigen of
Human Immunodeficiency Virus Type 1, 323 NEw ENG. J. MED. 1308, 1308-11 (1990); Daniel N.
Mendelson & S. Gerald Sandler, A Model for Estimating Incremental Benefits and Costs of Testing
Donated Blood for Human Immunodeficiency Virus Antigen (HIV-Ag), 30 TRANSFUSION 73 (1990).
122. See Harvey J. Alter et al., Prevalence of Human Immunodeficiency Virus Type I p24 Antigen
in U.S. Blood Donors-An Assessment of the Efficacy of Testing in Donor Screening, 323 NEW ENG. J.
MED. 1312, 1312-17 (1990).
123. The possibility remains, however, that supplementary antigen testing could be justifiable in
some geographic areas with very high IV infection rates. Proponents of decision support systems,
which are used to make difficult decisions under conditions of complexity and informational
uncertainty, have observed that hard decisions regarding optimal blood screening policies may be
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negligibly reduce the number of infected units of blood that enter the blood
supply. 24 Out of twelve million units of blood donated annually, they
estimate that presently around eighteen to twenty-seven units are
contaminated with IRV and that antigen testing might reduce these numbers
by approximately four to six units. 25However, one-quarter to one-half of all
transfusion recipients die within a year of transfusion from the medical
complications for which they received the transfusion, 26 thereby reducing
further the number of AIDS cases likely to be diverted by adding an antigen
test.
Other studies that focus on the costs of supplemental antigen testing
indicate that this duplicative process is enormously expensive. Using
estimates for the cost of an HIV-Ag antigen test, the number of blood
donations to be screened, and the number of AIDS cases that would be
averted by adding HIV-Ag testing to existing protocols, Professor Gelles
suggests an astounding cost of $24 million per AIDS case prevented.' More
recent estimates confirm Professor Gelles's finding that mandatory
supplemental antigen testing is financially unrealistic. Because all blood
donations would have to undergo the antigen test in order to achieve what are
presently small gains, 28 it is likely that the costs of supplementary antigen
facilitated by examining the varying dynamics that govern distinct population groups. Some
researchers, for example, have examined the costs of transfusing units of HIV-infected blood and
discarding units of uninfected blood associated with particular screening strategies. See J. Sanford
Schwartz et al., Strategies for Screening Blood for Human Immunodeficiency Virus Antibody, 264
JAMA 1704 (1990). Their findings suggest that different blood screening strategies should be adopted
according to "local differences in disease prevalence and incidence." Id. at 1707. The basic logic
behind this suggestion is sound: the costs associated with error in blood testing procedures are likely to
change as the risks of particular types of error change. Perhaps most importantly, the risk of false-
negatives increases for those populations at high risk for IV. Accordingly, retesting or second-
method testing procedures that cannot be justified for lower risk populations may be good policy if the
procedures can be directly targeted to higher risk groups. This reasoning suggests that decision support
systems can reduce the errors inherent in the transfusion of infected blood and the disposal of good
blood. The challenge in this regard is for investigators to develop more elaborate, precise models of the
risk postures of various donor populations, for which optimal screening policies can be tailored.
124. Eve M. Lackritz et al., Estimated Risk of Transmission of the Human Immunodeficiency Virus
by Screened Blood in the United States, 333 NEwENG. J. MED. 1721, 1725 (1995).
125. Id.
126. Id. at 1724.
127. Gelles, supra note 104, at 523-24.
128. See supra notes 121-27 and accompanying text. While it is difficult to imagine conditions
under which antigen testing might be improved sufficiently to justify its supplemental adoption in
industrialized nations, policymakers should consider technological improvements that could indicate a
need to revisit the question. One company, for example, has recently announced that it is near the
completion of machinery that could identify antigens within four days of HIV infection. Rebecca
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testing, like most forms of supplementary testing, 2 9 will prove financially
prohibitive. 3
For these reasons, antigen testing was justly deemed inadvisable by an
FDA advisory committee. 1 ' Notwithstanding the committee's
recommendation, the FDA advised blood banks in the summer of 1995 to
adopt supplementary antigen testing within three months of its commercial
availability.' The FDA's decision to mandate supplementary antigen testing
either ignores or neglects the cost side of prudent blood safety policy. Given
competing claims to scarce public resources, there must be a point at which
minimal numbers of diverted infections are considered an imprudent use of
vast amounts of tax dollars. Although the citizenry will never be brought to
concur on the precise location of that point, how many would fix it at $24
million per averted case of AIDS,'33 as estimated by Professor Gelles in
Rolwing, High-Tech Machine Speeds HIV Detection, BUS. J.-PHOENIX & THE VALLEY OF THE SUN,
Jan. 5, 1996, at 29, available in 1996 WL 8561084. This innovation could dramatically reduce the
opportunities for tainted blood to get into the blood supply during the serolatency window. While
sound policy will depend not only on the technology's effectiveness but also on cost considerations,
major improvements in antigen testing would certainly justify reexamination of otherwise rational
policies.
129. Given the effectiveness of the screening processes presently in place, assessments of the
supplemental value of antigen testing are likely to be representative of the cost-benefit structure of
other proposed supplemental tests, even the most effective ones. Existing procedures permit few
tainted units of blood to slip through the cracks. Accordingly, even screening processes that seem
relatively inexpensive per unit are unlikely to survive cost-benefit analysis, given the large volume of
units to be screened and the small number of incremental new infections that can be averted.
130. Because some readers will always object to the purported exchange of lives for money, even
few lives for much money, I emphasize here that difficult resource allocation decisions cannot be
avoided. At some point, dollars allocated for AIDS research, prevention, and treatment must be
distributed among competing claims and therefore must be assessed on the bases of effectiveness and
efficiency. My observation that supplementary antigen testing is likely to prove onerously and
intolerably expensive merely suggests that the large sums of money that would be consumed by the
test would probably save more lives if diverted to a more efficient use.
Drawing lines between acceptable and unacceptable costs for detecting tainted blood donations
certainly will be difficult. While most would likely agree that $36,300 is a reasonable social cost to
save one person from HIV infection, most would probably consider $24,000,000 too much, given
competing claims on public moneys. Although determining methods for establishing such precise cost-
benefit cut-off points is troublesome and goes beyond the purview of this Article, it is clear that
existing protocols for blood screening are advisable. As technology provides us with new methods of
improving blood screening effectiveness, we must assess each method to determine whether the
incremental costs are acceptable or whether the moneys should be diverted to other more productive
social ends.
131. See Antigen Memorandum, supra note 97. The committee disfavored antigen testing by a
nine-to-six margin. Id.
132. Id.; see also Man with AIDS Tests Negative for HIV, New Screening Plan Nears Approval,
L.A. DAILYNEWS, Mar. 8, 1996, at 16.
133. The relevant question for the citizenry to ask is whether 24 million dollars spent on
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regard to antigen testing?134
3. Informing Donors Whose Specimens Test Seropositive of Their HIV
Status
Once blood screening procedures are adopted, policymakers must decide
whether to inform contributors of infected specimens that they carry the
AIDS virus. From the inception of screening, the approach in the United
States has been to notify donors of seropositivity"' This approach enables
infected donors to seek treatment and avoid engaging in high-risk behaviors,
such as future blood donation attempts.
Conversely, India's policy has been to dispose of HIV-positive blood
without informing donors of their HIV status.'36 Commentators note that this
policy is attributable to concerns of maintaining confidentiality, avoiding
stigmatization, and avoiding communication of seropositivity in the absence
of counseling facilities. 137 India's approach also deters those who suspect they
are infected from donating as an indirect means of HIV testing. As one World
Health Organization ("WHO") representative has suggested, donors
motivated even in part by diagnostic considerations are particularly likely to
be high-risk candidates whose infected blood can pass into the supply during
the window period. 3 Should this be the case, a policy of informing donors
that their blood has tested seropositive could increase transfusion-associated
transmissions of AIDS.
None of the arguments on either side of the issue is patently spurious.
Choosing the optimal policy will depend on our ability to separate the
relevant arguments from the tangential or disposable ones, and then assess the
gains and losses associated with each option. The remainder of this
subsection addresses whether the benefits of informing donors of HIV status
educational and media abstinence campaigns, condom campaigns, needle exchanges, or AIDS research
can avert more than the single case of AIDS averted by spending those same dollars on supplemental
antigen testing.
134. See supra note 127 and accompanying text.
135. See Marlene Cimons, Notices ofPositive AIDS Tests Urged; Panel Would Tell Blood Donors
of Unconfirmed Results, L.A. TIMES, July 10, 1986, § 1, at 4 (discussing a federal advisory panel's
1986 determination that there is a "clear ethical responsibility" to inform individuals of any positive
test results, even those not confirmed by subsequent testing), available in 1986 WL 2182386.
136. Bhupesh Mangla, India: HIV-Positive Blood Donors, 341 LANCET 1527, 1527 (1993).
137. Id.
138. Id. (referring to the comments of Dr. Jai Narain, team leader of the New Delhi regional office
of the WHO Global Programme on AIDS).
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can be realized without incurring the losses that India's approach has sought
to avoid.
Concerns regarding stigmatization, breach of confidentiality, and lack of
counseling services are all manageable. Policymakers should not allow these
considerations to derail a choice that otherwise maximizes blood supply
purity. Stigmatization and confidentiality issues can be inexpensively and
effectively minimized through the adoption of protective procedures.'39 As
long as authorities provide effective, reliable assurances that test results will
remain strictly confidential, 4 ' donors will be protected from both publication
of their health status and any stigmatization that might subsequently result.
Confidentiality and concomitant protection from any stigmatization that
would result from a breach of confidentiality' are routinely and effectively
preserved by HIV testing clinics.'42 The procedures, rules, and other
safeguards adopted by these clinics to ensure privacy can easily be replicated
in blood collection centers.
Similarly, blood collection organizations can address counseling concerns
in the same way as HIV testing clinics.43 At least three options can be
139. Protective procedures are inexpensive to maintain. Confidentiality and the Irotection it
provides against stigmatization simply require self-monitoring by personnel in regard to (a) what
information they divulge to others, and under what conditions; and (b) the protection they use in
securing records. These procedures reflect care and responsibility in executing blood-collection tasks,
and need not exact significant implementation costs.
140. Confidentiality rather than anonymity is probably the best option here. Confidentiality
presumes that the donor will give his or her real name when donating blood, but that identification of
blood test results will be used only to protect the blood supply from immediate or future donations by
donors identified as seropositive. Anonymity would permit donors to give blood without identifying
themselves. While anonymity obviously provides more reliable assurances that the donor's identity
will remain secret, it is inconsistent with the utility of maintaining records that might screen out future
donations by a person whose blood tests positive.
141. For discussion of confidentiality and protection from stigmatization in regard to H]V status
generally, see Harold Edgar & Hazel Sandomire, Medical Privacy Issues in the Age of AIDS:
Legislative Options, 16 AM. J.L. & MED. 155 (1990); Paul M. Schwartz, The Protection of Privacy in
Health Care Reform, 48 VAND. L. REV. 295 (1995); and Peter J. Nanula, Comment, Protecting
Confidentiality in the Effort to Control AIDS, 24 HARV. J. ON LEGIS. 315 (1987).
142. See Roger Doughty, Comment, The Confidentiality of HIV-Related Information: Responding
to the Resurgence of Aggressive Public Health Interventions in the AIDS Epidemic, 82 CAL. L. REV.
111, 140 n.121 (noting that hospital and health clinic protocols often govern the handling of
information to protect confidentiality regarding HIV status).
143. The provision of effective counseling opportunities in conjunction with blood donation
requires special attention to the needs of donors. Blood donation centers are focused on the social end
of increasing the public blood supply. Unlike HIV-antibody testing clinics, they exist primarily to
serve society, not to serve the individual whose blood is being taken. Steve Connor & Sharon
Kingman, The Trouble with Testing, NEW SCIENTIST, Jan. 1988, at 60, 60. Accordingly, blood
collection centers will need to make concerted efforts if their attention is to be diverted to the needs of
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considered regarding the provision of counseling to donors informed that
their blood has tested seropositive: (i) mandatory counseling; (ii) counseling
available at the option of the donor; or (iii) no availability of counseling,
provided donors are informed prior to donation that no counseling is available
and that they will be informed of the seropositivity, if any, of their blood.
Because donors who arrive at blood collection sites may not expect to receive
information regarding their IIV status, many likely have not considered their
own capacity to process the life-altering knowledge that they are infected
with HIV. For this reason, counseling certainly should be available at blood
collection sites if a policy of informing infected donors of their serostatus is
adopted.Y The costs of maintaining this counseling function must be
incorporated into any calculation of whether to notify infected donors that
they are flV-positive. Whether such costs are minimal or substantial may
depend on whether the personnel who currently collect blood already possess
some or all of the professional training needed to engage in such counseling
and the degree to which one member of a collection team can specialize in
counseling, thereby minimizing the number of professionals who need
supplemental training.
A policy of informing donors of test results could have a more
troublesome effect: the encouragement of high-risk persons to donate blood
in order to learn whether they are infected with HIV. While this concern is
important, the history of public health policy in the United States suggests
that it is manageable. When blood screening practices were developed in
1985 to include a provision for informing infected donors of seropositivity,
policymakers concerned with the possible effects on blood supply safety
adopted an "alternative testing site program" that established a network of
clinics designated for HIV-antibody testing.145 Initiated before treatments for
IV infection and AIDS were available, the alternative testing sites were
opened primarily to provide those anxious about their HIV status with a place
donors. Informing seropositive donors of their HIV status and counseling them demands a substantial
shift in orientation.
144. Out of respect for the autonomy of individuals, blood centers should never coerce donors into
receiving counseling that they do not want, simply because a paternalistic authority has decided that
counseling is in their best interests. For a related discussion of mandatory versus optional counseling,
see Salbu, supra note 5, at 421-25.
145. See Public Health Service; Program Announcement; Alternative Testing Sites to Perform
Human T-Lymphotropic Virus-Type I (HTLV-Il) Antibody Testing; Availability of Funds for Fiscal
Year 1985, 50 Fed. Reg. 9909-10 (1985).
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to be tested without the subterfuge of an attempted blood donation.14 6
From its inception, the alternative testing site program has been highly
effective. In its first year, percentages of specimens found positive for HIV
antibodies were 432 times higher at alternative testing sites than at blood
banks. 47 Of the relatively small 0.04% of blood bank donations that tested
positive for HIV antibodies, 4 ' we can assume that some portion came from
people who had no suspicion that they were infected and who did not choose
blood donation as a method of indirect testing. Of the remainder who do
abuse blood donation procedures to discover their HIV status, blood
screening tests remain a highly effective safety measure that protects against
contaminated blood entering the supply.'49
Of course, despite these impressive statistics, some nominal margin of
contaminated blood units might be averted by adopting a policy against
informing donors of their seropositive status. However, the residual cost is
outweighed by the substantial benefits of notifying donors of their
seropositivity. First, a notified donor has the information necessary to "select
out" of attempting to make future donations. Left ignorant, a donor may try to
donate again, potentially contributing contaminated units of blood to the
supply. Second, a notified donor can avoid risky behaviors, such as unsafe
sexual practices or the sharing of injection paraphernalia, thereby averting
new infections. Third, given recent improvements in treatment for HIV
infection and AIDS, 5 ' the donor informed of seropositivity can begin
treatments that may avert suffering and extend life. The weight of these
benefits suggests that donor notification of IV status is sound policy,
provided that convenient and affordable alternatives exist to discourage using
blood collection centers merely to learn one's serostatus.'
146. Marvin E. Bailey, Developing a National HIV/AIDS Prevention Program Through State
Health Departments, 106 PUB. HEALTH REP. 695, 695-96 (1991).
147. Id. at 696.
148. Id.
149. For firther discussion of the effectiveness of blood screening tests in keeping HIV-infected
blood from entering the blood supply, see supra Section IV.A.
150. Protease inhibitors, fbr example, have shown promise for the treatment of HIV-1 infection.
See, e.g., Sven A. Danner et al., A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of
Ritonavir, an Inhibitor ofHIV-1 Protease, 333 NEW ENG. J. MED. 1528 (1995); Martin Markowitz et
al., A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection, 333
NEW ENG. J. MED. 1534 (1995).
151. Affordable, convenient alternatives are becoming increasingly available with the creation of
new technologies. For example, the development of HIV home-testing products improves the
accessibility of HIV-related health information. This convenient new method of learning one's IV
status should further reduce the temptation to use blood banks as HIV testing facilities. See Salbu,
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B. Prohibition of the Sale ofBlood Through a Mandatory All-Volunteer
Policy
Some health policy commentators recommend prohibiting the sale of
blood by individuals. This subsection addresses (1) the logic and history of
the prohibition of blood sales, (2) criticism of the prohibition of blood sales,
and (3) recommendations regarding the prohibition of blood sales.
1. Logic and History of the Prohibition ofBlood Sales
Policy distinctions made between sales and gratuitous donations of blood
are based on differences in motives. Whereas sellers may be motivated by a
desire or need for money, gratuitous donors are presumably' motivated by
altruistic impulses. 113 If sales are permitted, the greedy and the desperate may
sell blood that they know to be tainted.'54 Conversely, the generosity of
gratuitous donors encourages only those who believe their blood is pure to
contribute to the supply. Dramatic differences in seropositivity among paid
and unpaid donors tend to support this hypothesis.
5
The movement towards all-volunteer blood donation policies predates
AIDS. It was predicated on evidence that transfusion recipients developed
supra note 5, at 428-29 (discussing the increased accessibility of information regarding HIV status
conferred by home tests).
152. The presumption that altruism motivates voluntary blood donation may be somewhat
simplistic. In one bizarre instance, the Atlanta-Area Red Cross purportedly lost a number of donors
when it stopped giving Nutter Butter cookies out at donation sites. Eleena de Lisser, With a Cookie
Gone, Some Donors Threaten to Go, Too, WALL ST. J., Jan. 17, 1996, at Al. This seemingly absurd
reaction may indicate that the motivation to donate blood is affected by a number of factors that
comprise the whole experience of donating blood, some of which may be self-serving even in the
absence of actual payment For example, if the receipt of food and the opportunity to interact with
others motivate some donors, then altruism may not cause self-deferral by high-risk donation
candidates.
153. For a detailed examination of the altruistic nature of blood donation and a discussion of the
system in which blood is provided by gift rather than sale in the era of AIDS, see Thomas H. Murray,
The Poisoned Gift: AIDS andBlood, 68 MILBANK Q. 205 (Supp. 2, 1990).
154. See Larry Gostin, The Politics of AIDS: Compulsory State Powers, Public Health, and Civil
Liberties, 49 OHIO ST. L.L 1017, 1046 (1989) (noting that most intentional donations of HIV-tainted
blood involve payments).
155. Purchased blood is substantially more likely to be seropositive than donated blood. For
example, seropositivity among paid blood donors in India is as high as 75%, whereas seropositivity
among voluntary donors in India is 0.34%. Rachana M. Kumar et al., Letter to the Editor, HIV-1
Infection in Multi-Transfused Thalassemic Indian Children, 7 J. ACQUIRED IMMUNE DEFICIENCY
SYNDROMES 1211, 1211 (1994).
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hepatitis more frequently from sold blood than from donated blood.156 As
early as the 1950s, the hepatitis attack rate among recipients of sold blood
averaged 4.1 per 100 cases, whereas the hepatitis attack rate among recipients
of donated blood averaged 0.7 per 100 cases. 57 A number of subsequent
research findings have confirmed a higher hepatitis contagion risk associated
with the transfusion of commercial blood.158
By the early 1970s, a movement was formed against the use of "cash
blood," supported in large part by the work of the influential British professor
Richard M. Titmuss,5 9 who contended that market forces yield blood
products of a lower net quality than altruistic forces."6 Professor Titmuss
argued that the sale of blood creates incentives for blood sellers to lie about
medical conditions and histories, 6 ' thereby increasing the presence of
hepatitis in the blood supply. He also suggested that blood sales could cause
altruistic blood donations to decline, resulting in potential blood shortages. 62
In the wake of the hepatitis studies, Titmuss's book, and concerns that arose
decades later regarding HIV transmission, the United States gradually moved
156. J. Garrott Allen et al., Blood Transfusions and Serum Hepatitis: Use of Monochloroacetate
as an Antibacterial Agent in Plasma, 150 ANNALS SURGERY 455,458 tbl.3 (1959).
157. Id. at 457 tbl.2.
158. This higher risk has been associated with many types of hepatitis, including types B, non-A,
and non-B. See, e.g., Harvey J. Alter et al.. Posttransfusion Hepatitis After Exclusion of Commercial
and Hepatitis-B Antigen-Positive Donors, 77 ANNALS INTERNAL MED. 691 (1972); John H. Walsh et
al., Posttransfusion Hepatitis After Open-Heart Operations: Incidence After the Administration of
Bloodfrom Commercial and Volunteer Donor Populations, 211 JAMA 261 (1970). For a good review
of the research in this area, see Richard D. Aach & Richard A. Kahn, Post-transfusion Hepatitis:
Current Perspectives, 92 ANNALS INTERNAL MED. 539 (1980). But see Hepatitis from Blood
Transfusions: Evaluation of Methods to Reduce the Problem, Report to the Congress by the
Comptroller General of the United States, MND-75-82 (1976) (study refuting the relationship between
the sale of blood and the risk of hepatitis to transfusion recipients and suggesting that the
socioeconomic characteristics of donors are better predictors of hepatitis B antigen frequency rates
than the payment/nonpayment factor), cited in ALVIN W. DRAKE ET AL., THE AMERICAN BLOOD
SUPPLY 33-35 (1982).
159. See RICHARD M. TITMUSS. THE GIFT RELATIONSHIP: FROM HUMAN BLOOD TO SOCIAL
POLICY (197 1).
160. See id. at 150-52.
161. Id. at 151. This logic can be extended from hepatitis in the 1960s and 1970s to AIDS today.
Persons in some high-risk categories, such as intravenous drug users, may be more likely to sell blood
than the general population due to the financial exigencies associated with drug purchase and use. For
a discussion about seropositivity among HIV drug users who donate or sell blood, see Dale D.
Chitwood et al., The Donation and Sale of Blood by Intravenous Drug Users, 81 AM. J. PUB. HEALTH
631 (1991).
162. See TITMUSS, supra note 159, at 151 (suggesting that altruistic donors will increasingly be
unwilling to give blood as the number of profit-maling blood hospitals increases).
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to an exclusively gratuitous donor policy.63
2. Criticism of the Prohibition ofBlood Sales
Detractors have criticized the policy of prohibiting blood sales since its
inception. Some contend that banning blood sales can cause blood
shortages"6 at a time when supplies are especially vulnerable.'65 Other critics
163. In 1975, the Department of Health, Education, and Welfare established the American Blood
Commission ("ABC'), an association of private organizations engaged in blood banking and related
activities. Ross D. ECKERT & EDWARD L. WALLACE, SECURING A SAFER BLOOD SUPPLY: TWO
VIEWS 9 (1985). The ABC supported the concept of a noncash blood supply. Id.
Likewise, the FDA proposed regulations in 1975 to increase the proportion of noncash blood in
the overall blood supply. Whole Blood and Red Blood Cells: Label Statement to Distinguish Volunteer
From Paid Blood Donors, 40 Fed. Reg. 53,040 (1975) (proposed Nov. 14, 1975). As promulgated, the
regulations required blood products to be labeled according to donation source--either volunteer or
paid. Id.
Under present policy, all blood stored in blood banks comes from volunteer donors. Although
some plasma centers continue to purchase blood today, the products in which plasma is used are
treated to kill HIV and other contaminants. See Protecting the Nation's Blood Supply from Infectious
Agents: New Standards to Meet New Threats: Hearings Before the Subcomm. on Human Resources
and Intergovernmental Relations of the House Comm. on Gov't Reform and Oversight, 104th Cong.,
1st Sess. 157 (1995) (statement of Michael A. Foumel, Vice-President, Research and Dev., Bayer
Corp.) ("[P]lasma products.., are distinct from whole blood or blood components, especially because
technologies applied in the processing of plasma products involve multiple inactivation or clearance
steps that markedly enhance the safety of the final product relative to the starting material.").
164. Critical blood shortages have occurred periodically since all-voluntary blood donor policies
were adopted in the United States. See, e.g., Eileen Dempsey, Blood Donors Urged to Help Make Up
Shortage, COLUMBUS DISPATCH, Jan. 6, 1996, at 4B (reporting critical shortages in Ohio of 0-
negative blood, with less than one day's supply available); Linda Helser, Type "0" Blood Supply
Drops: Agency Sounds Alarm to Find Donors, ARIz. REPUBLIC, Jan. 5, 1996, at BI (reporting inability
of a non-profit blood provider to fill orders for types O-negative and O-positive blood); New York
Blood Center Declares Emergency Over, PR Newswire, Mar. 1, 1995, available in Westlaw,
PRWIREPLUS Database (citing the declaration of a blood emergency in New York City on January
23, 1995, which was exacerbated by national shortages, such that less than one day's reserves of 0-
positive blood were available).
Other countries have experienced similar blood shortages in recent years. See, e.g., Wendy Moore,
Health Changes: Blood Shed in the Service of the Nation, GUARDIAN (London), Oct. 26, 1994, at 6
(discussing recent blood shortages in Great Britain and offering various explanations), available in
Westlaw, GRDN Database; Adam Morawski, Blood Donor Scarcity, WARSAW VOICE, Dec. 11, 1994
(referring to recent blood shortages in Poland), available in LEXIS, News Library, Papers File;
Deborah Stone, Australia: Blood Bank is Bled White, SUNDAY AGE (Melbourne), Nov. 8, 1992, at 8
(reporting critical blood shortage in Australia), available in LEXIS, World Library, Txtlne File; Alison
Wiseman, Blood Donor "Red Alert" S. CHINA MORNING POST, Apr. 12, 1994, at 4 (reporting acute
blood shortage in Hong Kong and a plea made by the chief executive of one transfusion center
requesting blood donations), available in Westlaw, CHINAPOST Database; Blood Donors Ease
Shortage, TORONTO STAR, Dec. 29, 1994, at A6 (reporting critical blood shortage in central Ontario
and Toronto); Blood Shortage at KL Hospital Worst in 8 Years, STRAITS TIMES (Singapore), Feb. 23,
1995, at 18 (discussing a blood shortage in Kuala Lumpur).
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have suggested that Professor Titmuss neglects basic tenets of supply and
demand and that payment for blood should be expected to increase rather than
diminish blood supplies.'" Likewise, Russell Roberts and Michael Wolkoff
suggest that by distancing blood collection from the forces of supply and
demand, the all-volunteer policy impedes the market mechanism that helps
moderate overall quantity. 67 According to this suggestion, payment for blood
may be desirable as a means of maintaining adequate blood supplies in the
future. 6
8
Another group of commentators, some of whom concede the potential
public health benefits of an all-volunteer policy, have nonetheless observed
countervailing costs in the form of impaired property rights. 69 In this respect,
an all-volunteer policy imposes a "blood inalienability" rule-a property-
based rule that restricts "the [economic] transferability, ownership, or use" 7'
of one's own blood. Some have couched their critique of the blood
inalienability rule more specifically in terms of its disproportionate effect on
the poor,' 7' many of whom lose an especially important economic option
when restricted from selling their blood.
Others have questioned the accuracy of distinguishing between so-called
gratuitous blood and paid blood. Professor Ross Eckert notes that numerous
forms of non-cash compensation are frequently given in exchange for blood,
including tickets to theatrical or athletic events, food, wallets, tool kits,
165. Several factors may exacerbate blood supply shortages in the future. Significant numbers of
potential uninfected donors are disqualified from blood donation based on their personal histories.
According to one study, between 10% and 14% of adult males and 1% of adult females who are
otherwise suitable donors are disqualified on the basis of their personal histories. David I. Gregorio &
Jeanne V. Linden, Screening Prospective Blood Donors for AIDS Risk Factors: Will Sufficient Donors
Be Found?, 78 AM. J. PUB. HEALTH 1468, 1469 (1988).
Moreover, irrational fears associating blood donation with the risk of contracting AIDS are likely
to diminish donor pools. According to a 1989 survey, 20% of United States residents associate the
likelihood of contracting AIDS with blood donation. Diane M. Gianelli, Fewer People LinkAIDS with
Giving, Getting Blood, AM. MED. NEWS, Aug. 25, 1989, at 11.
166. See Hamish Stewart, Rationality and the Market for Human Blood, 19 J. ECON. BEHAV. &
ORG. 125, 127 (1992) (discussing reactions of economists to Professor Titmuss's influential work).
167. Russell D. Roberts & Michael J. Wolkoff, Improving the Quality and Quantity of Whole
Blood Supply: Limits to Voluntary Arrangements, 13 J. HEALTH POL. POL'Y & L. 167, 168-69 (1988).
168. Id. at 177.
169. See Susan Rose-Ackerman, Inalienability and the Theory of Property Rights, 85 COLUM. L.
REV. 931, 941 (1985) (suggesting that while "the use of a modified inalienability rule ... assure[s]
high quality blood supplies," it may impose high distributive costs on blood donors due to the lack of
compensation for blood donations).
170. Id. at 931.
171. See Madeline Morris, The Structure of Entitlements, 78 CORNELL L. REv. 822, 886 n.149
(1993) (stating that an inalienability rule "distribute[s] wealth away from the poor").
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photograph albums, leave time, credit, insurance, medals, and media
recognition. 72 Because these rewards have dollar-value equivalents,
Professor Eckert suggests that the prohibition of cash payments is inconsistent
with the legality of providing non-cash premiums.173
3. Recommendations Regarding the Prohibition of Blood Sales
The policy that prohibits cash payments for blood is sound. Purchased
blood is consistently documented as bearing a particularly high risk of HIV
contamination. 74 If we can maintain acceptable blood supply levels under a
no-cash policy, then the policy is rational. The desirability of the policy
decreases, however, to the degree that it contributes to dangerous supply
shortfalls across the globe.1'7 The more frequently that blood supplies become
inadequate, and the more severe the period of inadequacy, the greater the
social cost of the donor policies that contribute to the shortage.
176
Nonetheless, the sale of blood can be justified by compelling shortages
only if adequate supplies cannot be raised using less costly alternative means.
Should blood shortages become a serious problem, analysts should consider
ways of increasing the blood supply without resorting to payment for blood.
These might include, for example, increased budgets for the promotion of
gratuitous donations and the marketing of altruistic reasons to give blood.1
77
172. ECKERT & WALLACE, supra note 163, at 12. For anecdotal verification that blood donors are
sometimes remunerated in kind, see Patricia Nealon, They Give by the Gallon So That Others May
Thrive, BOSTON GLOBE, Feb. 21, 1996, (Metro), at 1 (quoting a former bank president who offered to
give employees a day off if they donated blood).
173. See ECKERT & WALLACE, supra note 163, at 13 ("The knowledge of having had hepatitis or
the incentive to conceal it might be no greater for someone who wanted to sell blood than for someone
who wanted time off from work, a turkey, or credit for a portion of a hospital bill.") (citing Reuben A.
Kessel, Transfused Blood, Serum Hepatitis, and the Coase Theorem, 17 J.L. & ECON. 265, 289
(1974)).
174. Cfsupra notes 156-58 and accompanying text.
175. See supra note 164.
176. Blood availability may be an increasingly important concern in years to come, as more
contributors are disqualified from donating or select themselves out of the donor pool based on
advancing age. Indeed, blood donations have dropped since the late 1980s. For example, 6.2 million
pints of blood were donated in the United States in 1987; by 1994, the figure had dropped to 5.4
million. Dan Wascoe, Jr., Blood Donation: High Profile May Mean High Turnout, STAR TRIB.
(Minneapolis), Jan. 22, 1996, at 3B.
177. Convincing the public to donate blood gratuitously is like any other marketing challenge.
While financial considerations are important, they are not the only way to recruit gratuitous donors.
Just as the seller of a product can compete on the basis of price or non-price characteristics, so public
policy can encourage blood donation using financial or nonfinancial inducements. Given that
payments increase the intentional provision of infected blood, it is reasonable to rely on nonfinancial
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Of course, should future technological and procedural improvements in blood
screening reduce the risk of error to virtually zero,'78 policymakers will need
to revisit the question of cash payments for blood.
Whether to treat paid blood differently from blood given for noncash
premiums should depend on the relative risks of each. If blood collected in
exchange for indirect or nonmonetary benefits is found to be as safe as
gratuitous blood, then the concerns of Professor Eckert'79 are academic rather
than pragmatic and should not be evoked to alter our present noncash blood
policy. If the conferral of perquisites yields blood that is safer than paid blood
but riskier than unpaid blood, we must weigh the incremental risk of
awarding perquisites against the benefit of augmented blood supplies. ° If
blood given for benefits in kind is as dangerous as blood given for cash, then
the two should be treated identically. In general, any similarities between cash
and noncash payments in encouraging the knowing donation of tainted blood
suggest that we may need to move away from all forms of compensation,
including compensation in kind.
Finally, the property rights of the population generally, and the poor
specifically, do not provide a compelling reason to permit cash payments for
blood. From a theoretical perspective, property rights are a social construct-
one's rights of ownership and alienation are not limitless, but rather depend
upon legal sanction.' Just as the state can prohibit the sale of drug products
inducements to market gratuitous blood donation to the public.
178. The elimination of errors requires not only ubiquitous adoption of effective procedures, but
also consistent implementation of effective procedures across all blood banks. Eradicating all sloppy or
negligent implementation of otherwise highly effective procedures will be an extremely difficult task,
given the limited budgets and ultimately autonomous operations of blood collection and distribution
centers. A recent blood scandal in Germany provides an example of that difficulty: a financially
strapped company economized on testing kits by pooling units of blood prior to actual testing, thereby
reducing the kits' effectiveness in detecting FHV antibodies. James 0. Jackson, Very Bad Blood: The
Discovery of HIV- Tainted Plasma in Germany Raises Alarm About the Ability to Ensure Safe Supplies
Worldwide, TIME, Nov. 15, 1993. at 65.
179. See supra notes 172-73 and accompanying text.
180. The logic attributing special danger to cash blood is less compelling in regard to noncash
premiums. The provision of cash creates a difficult moral peril for those who face financial exigency,
such as hungry people who are desperate to get food and addicted people who are desperate to get
drugs. This kind of desperation is far more likely to override moral qualms about selling tainted blood
for cash than a person's desire for time off the job or participation in insurance plans. Of course, under
this reasoning, the more liquid the noncash perquisite, the greater the chance that despair will override
ethical considerations. In this respect, items like easily scalped tickets to athletic events are likely to be
more dangerous donation premiums than medals or media recognition. These theoretical postulates
should be tested by data analysis that compares actual risks associated with various forms of noncash
incentives.
181. See Dorothy E. Roberts, Rust v. Sullivan and the Control of Knowledge, 61 GEo. WASH. L.
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that grow on an individual's land,' 2 it can legitimately prohibit blood sales
that pose a serious public health threat. Intransigent as the problem of poverty
has proven, it is reasonable to exclude one small alternative from the sphere
of possible solutions, particularly when that alternative is potentially life-
threatening to others.
C. Predonation Questioning and Disqualification ofDonations from
Persons in High-Risk Categories
Since scientists first noted a disproportionately high incidence of AIDS
among several groups,"8 3  predonation questioning and donation
disqualification procedures have become accepted practice in some countries.
This Section includes (1) a brief introduction to questioning and
disqualification procedures, (2) a history of the development of
disqualification criteria in the United States, and (3) an evaluation of the use
of questioning and disqualification procedures as a means of ensuring the
safety of the blood supply.
1. Questioning and Donation Disqualification Procedures
In the United States, blood collection centers and public health authorities
shield the blood supply from high-risk donations by educating the public
about groups that should not donate blood and by requiring people to "self-
defer" if they fall into any of the high-risk categories about which they are
informed prior to donation."s Furthermore, under federal law, the failure of
persons who have tested positive for HV to defer from donating blood is a
crime punishable by fine, imprisonment, or both.8 5
The self-deferral approach can be supplemented by prospective donor
questionnaires or interviews that disqualify those at high risk who fail to
REV. 587, 650 (1993) ("Property is a social construct.., that serves societal interests and its meaning
can be revised to accommodate changing views ofjustice.").
182. See 21 U.S.C. § 841(a) (1994) (prohibiting the manufacturing, distribution, or dispensation of
illegal drugs).
183. These groups include gay men, bisexual men, users of intravenous drugs, and their sexual
contacts. Daniel C. Berrios et al., HIV Antibody Testing Among Those at Risk for Infection: The
National AIDS Behavioral Surveys, 270 JAMA 1576, 1576 (1993).
184. Edward H. Kaplan & Alvin Novick, Self-Deferral, HIV Infection, and the Blood Supply:
Evaluating an AIDS Intervention, 14 EVALUATION REv. 686, 686-89 (1990).
185. 18 U.S.C. § 1118 (1994) (Protection against the human immunodeficiency virus, follows
§ 1121 and is the second of two sections 1118 in title 18 of the U.S. Code).
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select themselves out of the pool.18 6 Statistics suggest that these procedures
create a pool of relatively safe donors. In the United States, HIV antibodies
have been found in the blood of active donors only one-fortieth to one-
eightieth as frequently as in random population samples."i 7 Moreover, the
discovery in the early 1990s of persons who appear to have AIDS but test
negative for IV antibodies indicates the prudence of supplementing blood
tests with other forms of effective screening.' Because approximately three-
fourths of such persons fall within high AIDS-risk classes,'89 a policy of self-
deferral could substantially improve the quality of blood supplies. 9 '
Over the years, individuals have been categorically disqualified from
donating blood on the basis of two types of potential high-risk profiles-
those based on status and those based on behaviors. Disqualification based on
status rejects donations from persons describing themselves as belonging to
purportedly high-risk demographic groups. Disqualification based on high-
risk behaviors rejects donations from persons who report having engaged in
such risky activities as intravenous drug use or sexual intercourse with
prostitutes.' 9'
2. The Development ofDisqualification Criteria in the United States
In the United States, blood restrictions have evolved through years of
developing AIDS policy. In 1983, the Office of Biologics of the National
Center for Drugs and Biologics ("Office of Biologics") 92 recommended in a
186. This supplementary step appears to be necessary because potential donors are not highly
reliable at screening themselves. As one study found, "a small number of persons infected with the
AIDS virus continued to donate blood in spite of attempts to stop them, including giving them
literature explaining risks and recommending voluntary self-exclusion." Blood Supply Grows Safer,
FDA CONSUMER, Feb. 1990, at 5.
187. Roger Y. Dodd, The Risk of Transfusion-Transmitted Infection, 327 NEw ENG. J. MED. 419,
419(1992).
188. Rosenthal, supra note 78, at B2.
189. Cf id. (stating that about one-fourth of those with antibody-free AIDS-like symptoms fall
outside high-risk categories).
190. Because cases of antibody-free ADDS-like symptoms appear to occur infrequently, see id., the
magnitude of this improvement may be small.
191. See Revelle, supra note 30, at 23 (briefly discussing various high-risk behaviors that result in
permanent disqualification from donating blood).
192. The National Center for Drug and Biologics and its Office of Biologics were established as
part of the FDA in 1982. See 47 Fed. Reg. 26,913, at 26,913 & 26,919 (1982). Both were reorganized
two years later into the Center for Drug and Biologics ("CDB") and the Office of Biologics Research
and Review, respectively. See 49 Fed. Reg. 10,168, at 10,168 & 10,172-73 (1984). In 1987, the FDA
established two centers to replace the CDB: the Center for Drug Evaluation and Research ("CDER")
1996]
Washington University Open Scholarship
WASHINGTON UNIVERS1TY LAW QUARTERLY
memorandum ("1983 Memorandum") that blood collection establishments
institute educational programs to inform certain "increased risk" groups that
they should refrain from donating blood "until the AIDS problem is resolved
or definitive tests become available."'193 Under the 1983 Memorandum's
guidelines, the "increased risk" groups were defined as "persons with
symptoms and signs suggestive of AIDS, sexually active homosexual or
bisexual men with multiple partners, Haitian entrants to the United States,
present or past users of intravenous drugs, and sexual partners of individuals
at increased risk of AIDS."' 94 The Office of Biologics expressly designated its
1983 Memorandum as "an interim measure to protect recipients of blood and
blood products until specific laboratory tests [become] available."' 95
Since 1984, the-Office of Biologics has issued biannual revisions of the
exclusion categories, originally set forth in the 1983 Memorandum. Under the
1984 Revised Recommendations,' 96 the 1983 principles of donor screening
remained intact, but the list of persons to be instructed to refrain from
donating blood was modified. Persons with "signs or symptoms" of AIDS
remained excluded, and a list of indicia was attached.'97 While the exclusion
of intravenous drug users remained unaltered, the 1983 exclusion of "sexually
active homosexual or bisexual men with multiple partners" was changed to
"[m]ales who have had sex with more than one male since 1979, and males
and the Center for Biologics Evaluation and Research ("CBER"). See 52 Fed. Reg. 38,275 (1987).
Under CBER, the Office of Biologics Research and Review became the Office of Biologics Research.
See 53 Fed. Reg. 8978, 8979-80 (1988). For the sake of simplicity, this Article will use the term
"Office of Biologics" to refer to the Office of Biologics and its successors. The office is under the
umbrella of the Department of Health and Human Services ("HHS") and sends its memoranda out
under the HHS heading of"Public Health Service, Food and Drug Administration."
193. Memorandum from John C. Petricciani, M.D., Director, Office of Biologics, Nat'l Center for
Drugs and Biologics, Public Health Services, FDA, to All Establishments Collecting Human Blood for
Transfusion, Recommendations to Decrease the Risk of Transmitting Acquired Immune Deficiency
Syndrome (AIDS) from Blood Donors 1 (Mar. 24, 1983) [hereinafter 1983 Memorandum].
194. Id. at I (foomote omitted).
195. Id at2.
196. Memorandum from Elaine C. Esber, M.D., Acting Director, Office of Biologics Research and
Review ("OBRR"), Public Health Service, FDA, to All Establishments Collecting Blood, Blood
Components or Source Plasma and All Licensed Manufacturers of Plasma Derivatives, Revised
Recommendations to Decrease the Risk of Transmitting Acquired Immune Deficiency Syndrome
(AIDS) from Blood and Plasma Donors (Dec. 14, 1984) [hereinafter 1984 Memorandum].
197. Id. at 2. The signs and symptoms of AIDS were listed as
unexplained weight loss; night sweats; blue or purple spots typical of Kaposi's sarcoma on or under
the skin, or on the mucous membranes; swollen lymph nodes lasting more than one month;
persistent white spots or unusual blemishes in the mouth; fever [greater than] 990F for more than 10
days; persistent cough and shortness of breath; persistent diarrhea.
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whose male partner has had sex with more than one male since 1979." '' 9
"Patients with hemophilia' was added as a new excluded category, and
Haitians were restricted from donating only if they entered the United States
after 1977.'99 The 1984 Revised Recommendations contained a list of
appropriate medical screening questions" and emphasized the importance of
providing assurances of confidentiality in order to "increase the effectiveness
of voluntary self-exclusion procedures. ' 0 '
In 1986, the list of exclusions was revised to include
* persons with clinical or laboratory evidence of HTLV-IIILAV
infection;
" men who have had sex with another man one or more times since
1977;
* past or present intravenous drug abusers;
" persons emigrating since 1977 from countries where heterosexual
activity is thought to play a major role in transmission of HTLV-
III/LAV infection [e.g., Haiti, Central Africa];
• persons with hemophilia who have received clotting factor
concentrates;
* sexual partners of any of the above; and,
* men and women who have engaged in prostitution since 1977 and
persons who have been their heterosexual partners within six
months.
20 2
The 1986 revision contained procedures for maintaining the
confidentiality of exclusion, as well s a recommendation for written and
198. Id.
199. See id.
200. See id. at 2-3.
201. Id. at 3.
202. Memorandum from the Director of the OBRR, Center for Drugs and Biologics, Food and
Drug Administration, to All Registered Blood Establishments, Additional Recommendations for
Reducing Further the Number of Units of Blood and Plasma Donated for Transfusion or for Further
Manufacture by Persons at Increased Risk of HTLV-II/LAV Infection 1-2 (Oct. 30, 1986) [hereinafter
1986 Memorandum].
203. See id. at 2-3.
These procedures should provide at a minimum:
* that units designated not for transfusion to others be removed from inventories and not made
available for transfusion or for fiurther manufacture unless under a specific exception granted
in writing by the Director of the OBRR;
" strict confidentiality of donors' decisions and a confidential environment in which to make
the decisions;
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signed attestation by donors of their qualification under the revised
guidelines.2 4
The 1988 revision made only one change to the 1986 guidelines. In
recognition of the first case of HIV-2 infection reported in the United
States,"' the list of emigrants disqualified from donating blood was expanded
to include "persons emigrating since 1977 from countries where heterosexual
activity is thought to play a major role in [the] transmission of HIV-1 or HIV-
2 infection (e.g., Haiti, sub-Saharan Africa and islands located near these
areas of Africa). 20 6 Donations from otherwise qualified donors of stipulated
African nations were expressly authorized.2 7
In 1990, in a major reassessment of the bases for excluding blood donors,
the Office of Biologics made several significant modifications.0 8 Its revised
memorandum for that year limited the existing exclusion of potential donors
on the basis of national or geographical origin20 9 to "blood establishments that
have not implemented an FDA-licensed screening test for antibodies to HIV-
HTLV-mIILAV antibody testing of all donated units;
notification of all donors of the results of HTLV-III/LAV antibody tests considered positive
by the criteria defined in the procedure manual for that establishment, without regard to
whether they designated their units as acceptable for transfusion to others or excluded them
from transfusion to others;
* assurances to donors that units confidentially excluded will be used for laboratory testing.
Id.
204. See id. at 2. The memorandum recommended a provision like the following:
I have reviewed and understand the information provided to me regarding the spread of the AIDS
virus by donated blood or plasma and, if I consider myself to be a person at risk for spreading the
virus known to cause AIDS, I agree not to donate blood or plasma for transfusion to another person
or for further manufacture.
Id.
205. The first documented case of HIV-2 infection in the United States occurred in December
1987. AIDS Due to HIV-2 Infection-New Jersey, 37 MORBIDITY & MORTALITY WKLY. REP. 33, 33
(1988).
206. Memorandum from Elaine C. Esber, M.D., Director, OBRR, Public Health Service, FDA, to
All Registered Blood Establishments, Recommendations Conceming Persons at Increased Risk of
HIV-1 and HIV-2 Infection 1 (Apr. 6, 1988) [hereinafter 1988 Memorandum].
207. These nations included Morocco, Mauritania, Algeria, Libya, Egypt, Tunisia, Sudan,
Somalia, and Westem Sahara. Id.
208. See Memorandum from Gerald V. Quinnan, Jr., M.D., Acting Director, Center for Biologics
Evaluation and Research, Public Health Service, FDA, to All Registered Blood Establishments,
Revised Recommendations for the Prevention of Human Immunodeficiency Virus (HIV) Transmission
by Blood and Blood Products-Section I, Parts A & B Only (Dec. 5, 1990) hereinafter 1990
Memorandum].
209. For the 1988 Memorandum's version of this type of exclusion, see supra text accompanying
note 206.
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2." 2' Given the prevalence of HIV-2 antibody testing, the change has served
to virtually remove the national/geographic origin exclusions that existed in
previous memoranda. The change was purportedly predicated on findings that
better assurances of blood safety would result from "specific improvements in
donor education, including oral communication and direct questions about
risk behavior," '  without use of geographic deferrals. The 1990
memorandum emphasized risky behaviors over status under the theory that
the former provide a more accurate basis for excluding those at high risk. As
the author of the memorandum observed, "[t]he focus [of communications
with potential donors] should be on behavior and not on stereotypes (e.g.,
many men who have had male-to-male sexual experiences do not identify
themselves as 'homosexual,' 'gay,' or 'bisexual')."2"'
The remaining changes in the 1990 memorandum's list of exclusions
included the addition of one new category and the alteration of two existing
categories. The memorandum added as a new excluded group "[p]ersons who
have had, or have been treated for, syphilis or gonorrhea during the preceding
12 months."2 3 Two deferrals that existed in previous policy were extended
from six to twelve months-those who "engaged in sex with... [prostitutes]
during the preceding 12 months"24 and "[p]ersons who have received a
transfusion of whole blood or a blood component within the past 12
months." 2
15
As the Office of Biologics refines its recommendations, it should address
the continued need for categorical exclusions, given the trade-offs between
blood safety and the sufficiency of the blood supply. Once sound criteria for
exclusion are established, authorities should consider the effectiveness of
various procedures that can be adopted to optimize the effective
implementation of exclusions.
3. Evaluation of the Use of Questioning and Disqualification
Procedures as a Means of Ensuring Blood Supply Safety
Several critical issues must be addressed in assessing the value of
210. 1990 Memorandum, supra note 208, app. at 2 (Recommendations for the Prevention of
Human Immunodeficiency Virs (HIV) Transmission by Blood Products).
211. Id. at 1.
212. Id. at 2.
213. Id. app. at 2.
214. Id.
215. Id. app. at 2a.
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categorical exclusion policies. These issues include the need for categorical
exclusion in light of other safety shields, the optimal types of categorical
exclusions, and the optimal procedures for implementing these exclusions.
The value of categorical exclusions depends upon the extent to which
other methods of protecting blood, such as post-collection screening, leave
gaps in ensuring safety. The more accurate post-collection blood screening
becomes, the lower the incremental benefit of categorical exclusion, which
reduces the pool of prospective donors, thereby leading to potential shortages.
If blood screening becomes sufficiently accurate and blood supplies become
seriously impaired, categorical exclusion of high-risk donors could become
poor policy, imposing substantial costs while conferring negligible benefits.
Related to this analysis is a layer of issues that affect the value of all
categorical exclusion policies. These issues concern the degree of legitimacy
associated with characterizing particular statuses and behaviors as "high-
risk." Specifically, categorical exclusion policies should not be implemented
without consideration of the degree to which the risk of any targeted group
exceeds the risk of the population at large. The greater the degree of
incremental risk associated with a given status or behavior, the greater the
potential value of categorical rejection of blood originating from the class.
Small, nominal, or illusory differences in risk may not justify the elimination
of potentially large classes of blood contributors, particularly under
conditions of substantial blood scarcity and effective post-collection blood
screening. Accordingly, the 1983 categorical exclusion of blood from Haitianimmigrants in the United States"' was restricted in 1984 to Haitian
immigrants who entered the United States after 1977,2"7 based on a more
refined assessment of the risk associated with that particular status. Likewise,
the banning of blood donations by male homosexuals becomes less rational as
the incidence of HIV among all other groups continues to increase more
quickly than the incidence of HIV among male homosexuals.
218
A different form of error may be associated with dangerously
underinclusive definitions of excluded groups. Two early examples, the 1983
and 1984 exclusions which focused on gay men, provide cases in point. Both
216. See 1983 Memorandum, supra note 193, at 1.
217. See 1984 Memorandum, supra note 196, at2.
218. See Mark E. Wojcik, AIDS in the World, 16 HOUS. . INT'L L. 713, 713 (1994) (book review)
(citing "declining infection rates among gay men and increasing rates among heterosexuals'). For a
discussion of increasing HIV infection rates among heterosexuals, see Ed Susman, AIDS Epidemic
Spread in Heterosexuals, U.P.I., Jan. 31, 1996, available in LEXIS, News Library, Allnws File.
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exclusions are arguably arbitrary and irrational. The 1983 language, which
excluded "sexually active homosexual or bisexual men with multiple
partners, ' 2 9 appears to reflect either extreme nalvet6 or unconscionable
carelessness. In acknowledgement of the fact that monogamous donors
sometimes sleep with promiscuous mates, the exclusion was changed in 1984
to read as follows: "Males who have had sex with more than one male partner
since 1979, and males whose male partner has had sex with more than one
male since 1979."' This language contains two sources of error that could
impair the value of the exclusion. These are (i) the failure to exclude anyone
based on activities prior to 1979221 and (ii) the presumption that donors have
accurate knowledge of the outside sexual activities of their partners.
Presumably in light of these gaps, the exclusion was altered again in 1986 to
prohibit more broadly donations by "men who have had sex with another man
one or more times since 1977. "222
While potential error associated with class generalizations will invariably
undermine the utility of categorical screening, the exclusion of particular
groups of prospective donors can be effective if the groups are substantially
more likely to carry HIV than the donor population at large. In other words,
the potential benefits of categorical exclusion increase as the correlation
between class membership and HIV infection increases. This means that
highly accurate stereotypes can be an efficient and effective means of making
disqualification decisions regarding blood donations, whereas highly
inaccurate stereotypes are inefficient and ineffective.2"
219. 1983 Memorandum, supra note 193, at 1.
220. 1984 Memorandum, supra note 196, at 2.
221. This omission left a gap whereby persons infected with HIV through male homosexual
activities prior to 1979 were permitted to donate blood.
222. 1986 Memorandum, supra note 202, at 1.
223. On a continuum, consider perfect positive correlation between class membership and HIV
infection at one extreme, no correlation between class membership and HIV infection in the middle,
and perfect negative correlation between class membership and HIV infection at the other extreme.
When a perfect positive correlation exists, disqualification of all class members from blood
donation is efficient and effective. It is efficient because it permits accurate disqualification without
individual testing or assessment; it is effective because it disqualifies only infected prospective donors,
with no error. Accordingly, each categorical disqualification results in an avoidance of blood supply
contamination, and no categorical disqualification results in the rejection of a pure blood donation.
When no correlation exists, disqualification of all class members from blood donation is neither
efficient nor effective, as class membership is entirely unrelated to a donor's IV status. Class
membership thus becomes irrelevant to the goal of protecting the blood supply and provides an
irrational basis for making decisions.
Finally, when a perfect negative correlation exists between class membership and seropositivity,
disqualification of all class members from blood donation is most inefficient and ineffective.
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Accordingly, the primary criterion for scrutinizing any categorical
exclusion of donors should be the accuracy of the underlying stereotype.
Because IV is frequently transmitted through high-risk practices,224
behavior-oriented classes are likely to provide more accurate bases for
exclusion than status-oriented classes.25 Banning donations by male
homosexuals, for example, is subject to error associated with imperfect or
erroneous presumptions. Ceterispaibus, heterosexual females who engage in
unsafe sexual practices are at higher risk than homosexual males who are, and
have been, celibate.226 While such specific cases erode the reliability of status-
based classifications for excluding donors, the prudence of these
classifications ultimately depends upon the strength of the relationship
between status and behavior. For instance, the more likely male homosexuals
are to carry HIV relative to the population at large, the smaller the error
associated with the status-based classification.
An additional source of potential error associated with predonation
questioning and screening processes is the error related to response
inaccuracies. Even if a status-based classification is so highly correlated to
HIV infection as to render class membership an effective and efficient screen,
error can be attributed to both unintentional and intentional false reporting.
Such error can erode the effectiveness of categorical exclusions.
Both unintentional and intentional reporting errors can impair the value of
interrogation and categorical exclusion. Unintentional errors associated with
any self-reporting process can arise as a result of misunderstandings or
misinterpretations. 7 Moreover, unintentional errors in the self-reporting of
Disqualification of class members under such conditions is counterproductive, increasingly deterring
uncontaminated donations as the correlation approaches -1. Of course, policies of this sort are
inconceivable, and there is little need to worry about them in reality. They are mentioned here in order
to place the entire continuum of possible stereotypes in conceptual perspective. At some point, as we
move from a perfect positive correlation to a perfect negative correlation, the use of categorical
disqualification becomes sufficiently inefficient and ineffective that it is no longer a viable policy
consideration.
224. See generally MARK VARGO, THE Hiv TEST: WHAT You NEED To KNOW TO MAKE AN
INFORMED DECISION 18-34 (1992).
225. Status-based stereotypes entail the unavoidable inaccuracy that accompanies all stereotyping.
Even close correlation between a status and a behavior is attenuated by inevitable exceptions to status-
based generalizations.
226. Moreover, in some areas of the United States, heterosexual transmission has become the
predominant method of HIV transmission. See, e.g., Laurie Garrett, "Hetero " Sex Gaining as AIDS
Cause, NEWSDAY, Feb. 1, 1995, at A17 (noting that heterosexual transmission of AIDS has become
the leading method of transmission in the South Bronx).
227. Accordingly, experts emphasize the importance of clear, unambiguous questions in the
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class membership are likely to be exacerbated by the effects of cognitive
dissonance. Faced with the painful implications of high-risk activities, some
respondents may distort their perceptions of the severity of the risks that they
have taken. Likewise, some men may resist identifying themselves as
homosexual or acknowledging the hazards of sporadic unsafe sexual
relations. Accordingly, some who would objectively be considered as
intravenous drug users or homosexuals by virtue of their behavioral histories
might subjectively determine that they should not be so categorized.
Arguably, questions that seek behavioral rather than status information could
mitigate some of this inaccuracy by taking the responsibility of classification
away from the interested party (i.e., the prospective donor) and lodging it in
the hands of a more disinterested professional. Nonetheless, some degree of
error may still occur if respondents blur the characterization of what they
have done in the past or underestimate the quantity or severity of past
activities.
Error associated with inadvertent reporting inaccuracy is exacerbated by
some prospective donors' intentional misrepresentations. Given the
stigmatization of AIDS,22 homosexuality,229 and illegal intravenous drug
use, 230  some respondents feel pressure to lie when confronted with
predonation questioning.23' Such pressure can accrue at a number of stages
during various screening procedures. Respondents may be embarrassed to
answer truthfiflly either to a human questioner or on a form which will be
processed by a human questioner.3 2 Moreover, respondents may be
concerned that the information sought will not be kept confidential or will be
development of survey instruments. See, e.g., EARL R. BABBLE, SURVEY RESEARCH METHODS 128 (2d
ed. 1990).
228. See Doe v. Borrough of Barrington, 729 F. Supp. 376, 385 (D.N.J. 1990) ("Revealing that
one's family or household member has AIDS causes the entire family to be ostracized.").
229. Borquez v. Ozer, No. 93CA1805, 1995 WL 656871, at *5 (Colo. App. Nov. 9, 1995) ("[A]
strong stigma still attaches to both homosexuality and AIDS.").
230. See Note, The Constitutional Rights of AIDS Carriers, 99 HARV. L. REV. 1274, 1280 (1986)
(mentioning the stigma attached to AIDS as a result of "the disease's close association with both
homosexuality and intravenous drug use").
231. See Red Cross Had No Duty to Question Blood Donors, NAT'L L.J., Nov. 28, 1994, at B14
(observing adverse effect of the fear of stigmatization on accurate reporting by gay men regarding
sexual histories or partners).
232. The latter form of interrogation may be preferable to the former under the theory that
deception will be more frequent the more direct the human contact is in the questioning process.
Arguably, some persons who would lie to a human interrogator would tell the truth on a less
immediately confrontational form.
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used later in harmful or discriminatory ways. 3 Inevitably, a proportion of
respondents will respond to these fears by answering the screening questions
deceptively. The resulting error, combined with the potential error associated
with inadvertent false responses, may undermine the utility of status-based
classification as an accurate and useful screening tool.
Because of this potential pitfall, categorical exclusion policies should be
fashioned with an understanding of how certain procedures can reduce
inaccuracy and distortion. 4 Generally, computerized questionnaires are
superior to written questionnaires, and written questionnaires are superior to
face-to-face interviews. The logic behind this preference ordering is as
follows: Some false denials are given by self-aware respondents who admit
their engagement in high-risk activities to themselves, but are uncomfortable
admitting it to others. For these respondents, the more personalized the
method of information solicitation, the greater the potential discomfort.
Accordingly, relatively depersonalized written questionnaires should elicit
fewer lies than relatively personalized face-to-face questioning." Likewise,
233. This hypothesis is reasonable, given the high incidence of perceived discrimination based on
HIV-status. For example, during one six-month period in 1991, 104 cases of alleged HIV-status
discrimination were filed in Massachusetts alone. Laura Pincus, The Americans With Disabilities Act:
Employers' New Responsibilities to HIV-Positive Employees, 21 HOFSTRA L. REV. 561, 566 n.31
(1993).
234. While the procedures to be discussed may be helpful, they will not reduce all types of false
denials. Some false denials of high-risk behavior may be a projection of self-denial. When a
respondent is fooling not only the questioner but also himself or herself, the questioner cannot
reasonably be expected to identify false reporting in the interview process. We can only hope that
these cases are caught by ancillary nets, such as the blood specimen screening procedures discussed in
Section IV.A.
235. At least two possible explanations support this reasoning. First, even under conditions of
apparent privacy, the respondent who is speaking with a questioner is asked to identify risky behaviors
to someone who not only knows the respondent's name, but also can identify the respondent by
appearance. Second, if conditions of total privacy are compromised for any reason, whether it be
carelessness or expediency related to spacial limitations, the respondent may reasonably believe that
bystanders can hear his or her answers to the questions posed. I have witnessed, for example, blood
collection procedures that utilize one open room. The only privacy is that which is created through the
use of movable screens, which are of dubious value in obscuring view and of almost no value in
obscuring sound. This scenario is probably common, given that blood collection procedures frequently
occur in institutions that host blood drives using rooms that are only temporarily rearranged for blood
collection purposes.
Ironically, critics have cited Canadian procedures that use written questionnaires as less rigorous
than U.S. procedures, which require men to be asked face-to-face, "Have you had sex with a man since
1977?" See Mark Nichols & William Lowther, Setting Standards: How U.S. Rules on Blood Are
Tougher than Canada's, MACLEAN'S, Sept. 19, 1994, at 26 (discussing an FDA inspector's report
evaluating blood center practices in Toronto). Given the stigma attached by many to homosexual
behaviors, the use of written questionnaires as opposed to face-to-face interviews to elicit potentially
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computerized interview techniques are more highly depersonalized than
written questionnaires?36 and face-to-face interviews, and are therefore
superior in encouraging honest responses. 37
D. Regulations Requiring Improvements in Information Transmission,
Operating Procedures, and the Maintenance ofBlood Supplies
The quality of procedures adopted for the routine handling of blood can
affect levels of blood impurity and transfusion-associated contamination."8
Likewise, human error in the implementation of procedures threatens the
safety of blood supplies3 9 To address these problems, the U.S. Department
of Health, Education, and Welfare proposed a "National Blood Policy" in
1974 to centralize and standardize the collection and processing of blood for
distribution through regional blood banks.240 A variant of that proposed policy
was adopted later that same year.
41
Since 1974, the National Blood Policy has evolved in the United States
through a series of standards, rules, and approved manufacturing practices.
This Section examines the federal regulations that have been proposed or
sensitive or embarrassing information seems prudent.
236. Filling out written questionnaires entails a physical embodiment of information that can be
avoided through the use of computers. Donors may place greater confidence in the confidentiality of
the information they provide when they are asked to respond to questions on a computer terminal
located in a private setting, where onlookers are precluded from seeing their answers. This process
obviously avoids the personal contact of face-to-face questioning. It also avoids any passing of
tangible information on to blood bank personnel, who will presumably read the information
immediately and associate it with the person who has submitted it. When a respondent enters the same
information into a computer located in a private setting, he or she can see the questionnaire process
end and witness the computer resetting itself for another user without any tangible manifestation of
information. If these dynamics are indeed comforting to prospective donors, computerized donor
screening may be more effective than the use of written questionnaires.
237. See Steven E. Locke et al., Computer-Based Interview for Screening Blood Donors for Risk
of HIV Transmission, 268 JAMA 1301, 1304-05 (1992) (finding that computer-based interviewing
procedures elicited more self-reporting of high-risk behavior than Red Cross interviewing procedures
and that respondents exhibited a high degree of faith in the confidentiality of answers entered into
computers).
238. Cf Revelle, supra note 30 (discussing FDA regulation of the routine handling of blood to
ensure blood safety).
239. Ann Marie LoGerfo, Note, Protecting Donor Privacy in AIDS Related Blood Bank
Litigation-Doe v. Puget Blood Center, 117 Wash. 2d 772, 819 P.2d 370 (1991), 67 WASH. L. REV.
981, 996 (1992).
240. See National Blood Policy: Request for Comments Regarding Proposed Implementation
Plan, 39 Fed. Reg. 9329 (1974) (proposed Mar. 8, 1974).
241. See National Blood Policy: Department Response to Private Sector Implementation Plan, 39
Fed. Reg. 32,702 (1974).
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promulgated to improve operating procedures, the maintenance of blood
supplies, and the transmission of information. These regulations include (1)
labeling requirements, (2) required maintenance and filing of error and
accident reports, and (3) a proposed federal preemption of blood supply
regulation.
1. Labeling Requirements
In 1980, the FDA proposed extensive amended labeling requirements for
both blood and blood components as part of its revised "Current Good
Manufacturing Practices." '242 The proposed labeling requirements were
intended to simplify label information and to improve readability.243 They
also provided for computer coding of critical information as a means of
supporting the National Blood Policy goals of national coordination,
centralization, and regional interdependency among blood banks.2" The
ultimate aim was to develop and implement an automated data processing
system for the rapid, accurate distribution of blood products and to encourage
uniform labeling practices among all establishments that collect, process, or
label blood or blood components.245
The proposal to require machine-readable codification of labels was
rejected.246 Maintaining that computers could improve blood bank practices
and reduce error, the FDA nonetheless concluded that mandated bar coding
would impose an unjustifiable expense and burden on blood establishments
that were not yet computerized.247 Consequently, the FDA established a
voluntary adoption policy for the computer coding of labels, requiring only
that those who do use bar coding employ a system approved by the Director
of the Office of Biologics.2"
242. See Current Good Manufacturing Practice for Blood and Blood Components; Uniform Blood
Labeling, 45 Fed. Reg. 72,416 (1980) (proposed Oct. 31, 1980) (later approved and codified at 21
C.F.R. pts. 606, 640 (1996)).
243. Id.
244. See id. at 72,416-17 (codified at 21 C.F.R. §§ 606.121-.122 (1996)) (describing the computer
coding of labels as part of the implementation of the National Blood Policy).
245. See id. (stating that "interregional resource-sharing" among blood banks and "centralization
of blood collection" practices "predispose toward... implementation of an automated data processing
system... [and] the uniform placement of... encoded information").
246. 50 Fed. Reg. 35,458, at 35,461 ("FDA agrees it is unnecessary to require encoding.').
247. Cf id. ("[MFor those establishments that are not yet computerized ... , the direct benefit of
including encoded information on the container label would be minimal.").
248. See id. at 35,461-62.
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Although it rejected a mandatory computerized coding system, the FDA
approved labeling guidelines in 1985.249 The guidelines prescribe uniform
practices for the development and handling of blood labels and require
uniformity of information." The guidelines also require the physical or
spatial separation of labeling operations from other operations in order to
prevent mix-ups25' and mandate that labels "be held upon receipt, pending
review and proofing against an approved final copy, to ensure accuracy
regarding identity, content, and conformity with the approved copy. '25 2 In
addition, the guidelines require the storage and maintenance of each type of
label "in a manner to prevent mix-ups" and the destruction of "stocks of
obsolete labels. 25
3
The FDA labeling guidelines apply to all "blood products shipped in
interstate commerce. 254 Information required under the guidelines includes
identification of the unit's donor, 5 designation of whether the product is
intended for transfusion," and a "donor classification statement"257
identifying the source either as a "paid donor" 58 or a "volunteer donor."
259
The guidelines also require that blood not intended for transfusion be labeled
accordingly" and include the reason for its unsuitability.
261
The FDA labeling guidelines are sensible, cost-efficient mechanisms for
improving blood safety and avoiding unnecessary error. Blood products
obviously must be designated in terms of the presence of contaminants, and
249. See Final Rule, Current Good Manufacturing Practice for Blood and Blood Components;
Uniform Blood Labeling, 50 Fed. Reg. 35,458 (1985) (codified at 21 C.F.R. pts. 606, 640 (1996)).
250. See generally 21 C.F.R. pts. 606, 640 (1996).
251. Id. § 606.120(a).
252. Id. § 606.120(b)(1).
253. Id. § 606.120(b)(2).
254. 50 Fed. Reg. 35,458, at 35,460 (1985).
255. 21 C.F.R. § 606.121(c)(3) (1996).
256. Id. § 606.121(c)(5).
257. Id.
258. A "paid donor" is defined as "a person who receives monetary payment for a blood
donation." Id. § 606.121(cX5)(i).
259. A "volunteer donor" is defined as "a person who does not receive monetary payment for a
blood donation." Id. § 606.121(c)(5)(ii). Persons who receive nonmonetary benefits are considered
voluntary donors. See id. § 606.121(c)(5)(iii). The FDA reasons that (1) "the higher risk of
posttransfusion hepatitis associated with blood from paid donors results primarily because direct
monetary payment for blood attracts donations from persons from socioeconomic groups with
prevalent transmissible hepatitis" and (2) nonmonetary incentives are "not as likely to attract persons
from groups with a high risk of hepatitis." 50 Fed. Reg. 35,458, at 35,460 (1985).
260. See 21 C.F.R § 606.121(f) (1996). This requirement applies only to products not labeled "for
noninjectable use only." See 50 Fed. Reg. 35,458, at 35,464 (1985).
261. See21 C.F.R. § 606.121(f) (1996).
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federal regulation of labeling provides a consistency that helps to reduce
errors, careless practices, and misinterpretations of designations. While the
FDA's approach to labeling has been sound, the agency should revisit the
question of mandatory machine-readable labels. Given the rapid diffusion of
technology since the FDA rejected the proposed requirement in the early
1980s, the benefits of requiring computer bar coding are likely to have
increased substantially, particularly over the past five years. Accordingly, it is
time to calculate anew the costs and benefits of requiring the use of blood and
blood product labels that can be read using automated processes.
2. Required Maintenance and Filing ofError and Accident Reports
Errors and accidents reported annually to the FDA by blood banks have
risen from approximately one thousand in 1989 to approximately ten
thousand per year in the early 1990s.262 These numbers may understate the
incidence of errors and accidents, given alleged deficiencies in the FDA's
blood supply monitoring processes.2 63 A recent government audit, conducted
by the Inspector General of the Department of Health and Human Services,
concluded that the FDA is lax in the timely collection of hospital and blood
bank "error reports."' The audit report requested the promulgation of FDA
regulations that would require blood suppliers to account for, and control
damage quickly in the event of, accidents and mistakes. 265 An FDA
spokesperson agreed that gaps existed with respect to accountability for blood
safety and stated that the agency was working on "proposals to require all
facilities to submit error and accident reports. 266
This endeavor is critically important to maintaining the safety of the blood
supply. Error and accident reports help blood banks to identify persons at risk
and to recall tainted blood as quickly as possible.267 Such reports also help the
FDA to monitor blood bank operations.26' Finally, the accumulation of
262. See Richard J. Newman et al., Bad Blood, U.S. NEWS & WORLD REP., June 27, 1994, at 68,
70.
263. See generally Linda M. Dorney, Comment, Culpable Conduct with Impunity: The Blood
Industry and the FDA's Responsibility for the Spread of AIDS Through Blood Products, 3 J.
PHARMACY & L. 129 (1994).
264. See G. Pascal Zachary, FDA Can Improve Safety of Blood with Better Data, WALL ST. J.,
June 5, 1995, at B3.
265. See id.
266. Id. (quoting FDA spokesperson).
267. See id.
268. In 1993, for example, the American Red Cross entered a consent decree with the FDA in
[VOL. 74:913
https://openscholarship.wustl.edu/law_lawreview/vol74/iss4/2
1996] AIDS AND THE BLOOD SUPPLY 961
reports over time is essential to the development of a history and collective
memory of the kinds of errors that are made. Aggregating data from a wide
variety of blood supply situations over an extended period of time permits
detailed analysis and understanding of the sources of blood processing
mistakes, as well as their potential avoidance or rectification.
3. Proposed Federal Preemption ofBlood Supply Regulation
Recently, a number of influential blood suppliers269 have petitioned the
FDA to consider preempting state and local regulations concerning donor
suitability and other issues."' The petition notes that blood today moves
"extensively and continuously in interstate commerce."27 It further contends
that FDA regulation of the collection, processing, labeling, and distribution of
blood and blood components is extensive and overlaps a patchwork of state
regulations that purportedly threatens the adequacy and safety of the blood
supply.272 In terms of adequacy, the petitioners suggest that "without a
uniform regulatory scheme, the nation's vital interest in the free flow of blood
components and derivatives across State and local borders, as well as between
the United States and its foreign trading partners, is in jeopardy."273 In regard
to safety, the petitioners argue that "[s]tate action can actually decrease blood
response to allegations that it had violated blood safety laws. John Schwartz, Red Cross, FDA Agree
on Blood Safety Regulations, WASH. POST, May 8, 1993, at A5. The allegations included inadvertent
distribution of hepatitis-contaminated blood, failure to follow safety precautions, and failure to report
accidents and errors to the FDA. Id. Among the measures required by the consent decree, which
strengthened FDA authority over Red Cross blood banks, were improved quality assurance and
training of personnel, and stronger policies for the investigation and reporting of accidents and errors.
Id.
The FDA has also threatened to close local blood banks for failure to comply with safety
standards. One blood bank in San Francisco was cited in 1993 for purported violations in record
keeping, blood testing, and blood labeling. Charles Petit, FDA Threatens to Close Irwin Blood Bank,
S.F. CHRoN., July 21, 1993, at Al. The FDA suspended the licenses of a Spokane blood center that
same year, effectively barring the center from the interstate shipment of blood and blood products.
Blood Center Licenses Suspended, FDA CONSUMER, July-Aug. 1993, at 6.
269. The group included the American Blood Resources Association, the American National Red
Cross, the American Association of Blood Banks, and the Council of Community Blood Centers.
Notice of Citizen Petition Requesting Federal Preemption of Certain State and Local Standards
Affecting Blood, Blood Components, and Blood Derivatives, 58 Fed. Reg. 45,341 (1993).
270. Id. In addition to preemption of state and local regulations regarding donor suitability, the
petition also requests preemption of state and local regulations on testing and labeling of blood, blood
components, and blood derivatives. Id.
271. Id.
272. See id. at 45,342.
273. Id.
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safety by mandating poorly thought-out schemes that may overwhelm the
limited resources available to blood establishments and cause paradoxical
outcomes.
' 274
Federal preemption of blood supply regulation is long overdue. Any
reason for maintaining state and local control, such as regional
epidemiological variations, becomes decreasingly compelling as AIDS
becomes increasingly pandemic. Likewise, the benefits of uniformity in
labeling and other procedures, as discussed in Section IV.D.1, would be
supported by the implementation of a single, consistent federal blood policy.
Finally, the ongoing threat of blood shortages, 75 exacerbated by the
heightened screening and disqualification of donors recommended in this
Article, suggests a growing need to shift blood between regions. The
emerging nationalization of the blood supply suggests that blood safety is
becoming more a federal issue and less a local one.
E. Development and Maintenance oflnformation Registries
The establishment of information registries can help blood collection and
distribution authorities to monitor and control potential sources of impure
blood. This Section addresses (1) the potential benefits of information
registries and (2) the potential abuses and related costs associated with
information registries.
1. Potential Benefits ofInformation Registries
In a number of countries, including the United States, registration
mechanisms called "donor deferral registries" ("DDRs") have been adopted
to screen out potential donors who previously have been disqualified from
giving blood.276 Varieties of DDRS differ primarily according to the scope
and degree of centralization. Many blood banks maintain local records of
prospective donors whose blood has been rejected for seropositivity.277 These
274. Id.
275. See supra notes 164-65 and accompanying text.
276. Venezuela, the Philippines, Germany, and Canada are other countries that maintain such
registries. D. Reviron et al., Prevention of HiY Infection by Transfusion: Comparative Analysis of
Systems Adopted in Developed Countries, 6 AIDS & PUB. POL'Y . 25, 26 (1991).
277. In the early 1990s, the Red Cross began implementing a national computer system to
centralize records and information regarding those who donate blood at any of its centers in the United
States. See Christine Woolsey, Proposals Target Safety of Blood, Tissues, BUS. INS., May 27, 1991, at
3, 3. The system allows any center to retrieve health histories and test results of donors who have been
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localized DDRs can be made more comprehensive and inclusive through
participation in computerized databases that provide access to the identity of
large numbers of rejected donors across blood banks, states, or nations.278
The potential benefits of DDRs are a function of the degree to which
collected information results in the accurate rejection of tainted blood that
otherwise would have entered the blood supply.279 Reference to DDRs averts
blood-supply contamination primarily when a seropositive donor tests falsely
negative but is traced to a prior disqualification for having tested positive. Yet
under today's screening technologies, the probability of a false negative test
result is low.28 Moreover, in countries where the sale of blood is banned,
donors presumably act out of charitable impulses and are therefore unlikely to
attempt second donations after a previous disqualification.28' As voluntary
abstention practices approach ubiquity, the risk of contaminated donations by
persons previously disqualified for seropositivity approaches zero.282 For
these reasons, the incremental protection of the blood supply provided by
DDRs may be insubstantial.
Although they may avert only a small number of contaminations,
registries have the potential to serve other useful functions. For example,
accurate recordkeeping is an essential precursor to the ex post facto tracing
procedures discussed in Section IV.F. Unfortunately, the sources of the blood
deemed unsuitable. Id.
278. Local blood banks that are unaffiliated with the Red Cross sometimes operate local DDRs
whose effectiveness is limited because they are not connected to large, nationwide networks. See
McCullough, supra note 116, at 2241. Presently, the American Red Cross operates a single,
centralized DDR that provides any location with access to information obtained at any other location.
Id.
279. As McCullough observes, these benefits have not yet been established. Id. Prudent policy
therefore depends on studies that indicate marginal effectiveness and assess countervailing costs.
280. See Kimmig, supra note 101.
28 1. Conversely, in places where blood sale is permitted, greed and desperation might motivate
some to attempt to sell their blood despite knowledge of infection. Self-serving motives may be
particularly compelling when combined with drug addiction, which can increase both the desperation
and the irrationality of prospective blood sellers. Because needle sharing among intravenous drug users
is a significant means of H1V transmission, these risks will not be insignificant.
282. Of course, voluntary abstention by those who know themselves to be seropositive will never
be ubiquitous. Whereas the optimistic might expect all donors rejected for seropositivity to screen
themselves out as future donors, not all persons are rational, mentally stable, and virtuous. While rare,
cases of purportedly intentional transmission of IV do exist. See, e.g., State v. Stark, 832 P.2d 109
(Wash. Ct. App. 1992).
In addition, we cannot discount instances in which rejected, seropositive donors attempt to make
second donations, either because they are not of sound mind or because they lack the rationality or
intelligence to understand the ramifications of such an act.
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transfused to a donee are not consistently and routinely recorded.2"3 Records
might easily be maintained to identify the sources of blood associated with
individual transfusions. 2 4 Such records would permit authorities to
investigate the history of blood units determined after transfusion to have
been seropositive.8 5 The identified recipients of tainted blood could then be
informed of their exposure in order to be tested for HIV and to modify
behaviors that risk new transmissions.
The existence of records and procedures for informing recipients of
tainted blood may also alleviate the fears of transfusion donees who have
received untainted blood concurrent with any tainted blood incidents. This
may be beneficial not only in reducing anxiety among the affected donees,
but also in reducing public fears regarding the risks of transfusion in
general. 2
86
2. Potential Costs ofInformation Registries
The potential benefits of maintaining information registries must be
balanced against potential costs. In addition to the obvious implementation
costs,287 plausible social costs fall into three general categories: (a) invasion of
privacy, (b) risk of discrimination, and (c) chilling effect on blood donation.
a. Invasion of Privacy. Information regarding HIV status is private
information.88 The privacy concerns of individuals regarding HIV and AIDS
283. Ralph R. Frerichs & Eugene Seymour, Letter to the Editor, HIV Testing and Blood
Recipients, 342 LANCET 1549, 1549 (1993).
284. Some commentators have recommended mandatory notation of a blood unit's source on all
patient casenote records. See James J. McMenamin et al., Letter to the Editor, HIV Testing and Blood
Recipients, 343 LANCET 478 (1994).
285. For an example of a laboratory in the United Kingdom that has adopted this process, see
Patricia E. Hewitt, Letter to the Editor, HIV Testing and Blood Recipients, 343 LANCET 797 (1994).
286. Of course, post-transfusion information regarding contaminated blood sources cannot undo
the potential exposure to HIV. Such information, however, may increase public trust by demonstrating
that the relevant professionals behave responsibly and handle errors openly and honestly.
287. These costs include personnel hours and overhead expenses dedicated to the maintenance of
records, hard-copy records and storage space, computer facilities, and computer programs.
288. Facts concerning a person's infection or illness, especially with respect to a stigmatized
disease like AIDS, are fundamentally personal. See Urbaniak v. Newton, 277 Cal. Rptr. 354, 360 (Cal.
Ct. App. 1991) (describing seropositive status as "a private fact" to persons "of ordinary sensibilities")
(quoting Forsher v. Bugliosi, 163 Cal. Rptr. 628, 637 (Cal. 1980)); see also Carol A. Tauer, AIDS and
Human Rights: An Intercontinental Perspective, in AIDS: ETHICS AND PUBLIC POLICY 154, 159
(Christine Pierce & Donald Vandeveer eds., 1988) (listing "the right of personal privacy and
confidentiality regarding medical and sexual information" as a right that AIDS control measures can
threaten).
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are heightened by potential misunderstanding of the virus and the disease, as
well as by ostracism, stigmatization, and discrimination.289
Any use of HIV-status information evokes privacy concerns.' 9° The
degree of concern will vary according to the nature and extent of potential
publication and associated risks. At one extreme, publication of the identities
of those exposed to HIV would raise serious objections because the
announcement of personal information would be far-reaching and the risks to
the individual would be high. At the other extreme, a central registry which
employs substantial privacy safeguards might be maintained. The safeguards
might include legal or regulatory assurances of confidentiality, as well as
structural protections to discourage any breach of the legal and regulatory
constraints. Structural protections typically take the form of rules and
procedures limiting access to registry information, maintaining high levels of
security for computerized database information, training personnel with
regard to the legal and ethical issues associated with privacy, and penalizing
with adequate severity those who violate the privacy rights of others. Unless
implementation of such precautions should prove ineffectual in preserving
privacy interests,29' lawmakers and policymakers should not presume that
privacy concerns are unmanageable. Given the benefits of recordkeeping,
authorities must consider and test administrative controls that are potentially
powerful tools for the maintenance of privacy.
As we shall see in Section IV.E.2.b, the information kept in central
registries can be used for discriminatory purposes if privacy protections are
suboptimal. Moreover, the fear of privacy infractions and the negative results
of publication can reasonably be expected to have a chilling effect on donor
activity, even if those fears are exaggerated or irrational.
289. See INSTITUTE OF MED., NAT'L ACADEMY OF SCIENCES, CONFRONTING AIDS: DIRECTIONS
FOR PUBLIC HEALTH, HEALTH CARE, AND RESEARCH 133-35 (1986); see also INSTITUTE OF MED.,
NAT'L ACADEMY OF SCIENCES, CONFRONTING AIDS: UPDATE 1988, at 62-64 (1988) (discussing
studies and cases illustrating AIDS-based discrimination).
290. See Doughty, supra note 142, at 163-77 (suggesting that AIDS patient confidentiality is
inadequately protected in relation to some public health policies).
291. While the listed precautions will mitigate both potential privacy violations and individual
fears of such violations, they can never guarantee total compliance with regulatory or legal edict. Use
of centralized registries requires the identification of individuals in order to serve the screening
functions for which they are established, and some human beings will ultimately have access to that
information as data are entered, processed, and used. While the potential for lapses decreases when
extreme care is exercised, it is impossible to eliminate entirely the potential for abuse. Moreover, not
all laws, regulations, and structural implementation systems will employ meticulous care in
considering individual privacy rights. Use of central registries without powerful safeguards will
inevitably create serious risks of breach of privacy.
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b. Risk of Discrimination. Discrimination against persons with HIV or
AIDS is well documented.292 As observed in the previous discussion, the
potential for discrimination heightens the individual's privacy stakes.
Whereas some choose to reveal their HIV status to the world, others treat this
information as purely personal. An important aspect of one's privacy interest
in lIV-status information is the freedom to choose whether to risk public
disclosure and possible exposure to discrimination.
While statutory protection against discrimination applies to people with
AIDS ("PWAs") under the Americans with Disabilities Act ("ADA"),293 the
potential for insidious discrimination remains high. Like all anti-
discrimination laws, laws prohibiting discrimination against PWAs protect
only against patent or ill-concealed abuses.294 Because motives exist in the
mind of the individual, they are subject to degrees of concealment and
subterfuge.295 A prospective discriminator who is clever and reasonably well
versed in the law can achieve a discriminatory goal while leaving no evidence
of discriminatory motives.296
These observations are made in order to emphasize a crucial consideration
with respect to centralized registries: if lapses in privacy occur and the
information contained in centralized registries is publicized, recipients can
use the information for easily veiled discriminatory purposes. The difficulty
in enforcing anti-discrimination laws arguably heightens the importance of
curbing the flow of private information. Obviously, the ultimate method of
ensuring complete privacy would be to maintain donor anonymity and
decline to keep records of donor status.
Such a potent safeguard against discrimination must be weighed against
the potential benefits of central registries, to determine the net utility of
292. See Michael Closen et al., Mandatory Premarital HIV Testing: Political Exploitation of the
AIDS Epidemic, 69 TUL. L. REV. 71, 72 n.3 (1994) (citing sources that discuss the stigmatization of,
and discrimination against, persons with HIV and AIDS).
293. See Adrienne L. Hiegel, Note, Sexual Exclusions: The Americans With Disabilities Act as a
Moral Code, 94 COLUM. L. REV. 1451, 1472 (1994) ("AIDS is clearly intended to be a per se
disability under the ADA .. .
294. Accordingly, pretext has become a prominent issue in discrimination cases. See generally
Catherine I. Lanctot, The Defendant Lies and the Plaintiff Loses: The Fallacy of the "Pretext-Plus"
Rule in Employment Discrimination Cases, 43 HASTINGS L.J. 57 (1991).
295. "[M]otives are seldom apparent or vocalized." Charles G. Burgess, Recent Decision, Ex
Pane Scarbrough, 46 ALA. L. REV. 211, 223 (1994) (quoting State v. Bruzzese, 463 A.2d 320, 326
(N.J. 1983)).
296. By thoroughly documenting pretextual motives, for example, the discriminator may be able
to present a plausible legal basis for what is actually an act of illegal discrimination.
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elaborate recordkeeping. Because increased opportunities for discrimination
attributable to the maintenance of information registries ultimately depend on
some breach of privacy, the arguments raised in the preceding subsection
apply in this subsection as well. If administrative safeguards can be developed
to maintain privacy interests effectively, then marginal instances of
discrimination enabled by registries will be negligible or nonexistent. Various
promising combinations of procedures, rules, regulations, and penalties can
and should be tested and evaluated to determine the unavoidable costs of
maintaining information registries.
c. Chilling Effect on Blood Donation. The maintenance of records
identifying persons who have tested seropositive could have a chilling effect
on blood donations."l This observation is the logical extension of the
phenomena identified in the preceding two subsections. Both incursions upon
privacy and misuse of information are negative factors in an individual's
decision to donate blood.
A potent fear for donors under information registration systems is fear of
litigation-that the recipient will sue the donor should the donated unit prove
seropositive, or that the donor will be subpoenaed for discovery in connection
with a suit by the recipient against the blood bank. Sufficiently escalated,
such fears could chill blood donation and exacerbate blood supply shortages.
One court has suggested that the identification of donors for discovery
procedures can facilitate the administration of justice without undue social or
personal cost. In Watson v. Lowcountry Red Cross,9 ' the Fourth Circuit
Court of Appeals upheld the district court's limited discovery procedures,
under which a deposed donor's identity was disclosed only to the court and
the donor's court-appointed attorney."9 Discovery took the form of written
297. It is also conceivable, albeit less likely, that the use of centralized registries could dissuade
some persons from being tested for IUV. This situation would certainly be true if centralized registries
were expanded to include the identities of all who test seropositive, whether blood donors or not. But a
similar situation could occur under a more limited scheme being addressed herein-the registration
only of those who test positive after donating blood. This kind of chilling effect on HIV testing could
be a function of mistrust, ignorance, or both. Persons considering HIV testing might not believe that
registries are limited to blood donors, or they may have imprecise information that registries exist in
some contexts, the specific boundaries of which are unclear. As the public gains accurate or inaccurate
information about the existence of some kind of registry of persons who have tested positive for HV,
suspicion of testing in general might well arise. Whereas a chilling effect on blood donation among
members of high-risk groups arguably could be beneficial, a chilling effect on HIV testing among
members of high-risk groups is detrimental. Those considered most at risk are also among those most
likely to benefit from early medical intervention resulting from diagnostic Hv testing.
298. 974 F.2d 482 (4th Cir. 1992).
299. Id. at 489.
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questions given to the donor by the donor's lawyer and returned to the district
court.00 The Red Cross contended that permitting even limited identification
and shielded deposition of donors would jeopardize the blood supply by
discouraging donations and that the discovery violated the donor's privacy
rights.30' The Fourth Circuit supported the district court's finding that such
limited discovery would have no appreciable negative impact on the blood
supply and noted that the questions to be asked during deposition were no
more intrusive than those which the Red Cross is required by law to ask prior
to donation.3 °2
It has been suggested that in light of Watson, suppliers should reassure
donors that the "decision does not condone public disclosure of a donor's
identity and background" and that "[o]nly in the event of a lawsuit will a
blood supplier be required to reveal a donor's identity, and then only to a
court."3 3 While this advice may encourage donations, it is misleading and
could convey a false sense of security to prospective donors. First, the Watson
decision is not binding in jurisdictions outside the Fourth Circuit. Second,
even in the Fourth Circuit, the decision does not require that donor
identification be shielded during donor discovery. Rather, it affirms that one
trial court's approval of such procedures was not erroneous.3 ' In the wake of
Watson, future Fourth Circuit courts could consistently approve more
intrusive donor identification procedures that fail to protect donor identity.
Given the holding in Watson, prospective donors may indeed worry about
being sued or subpoenaed as a result of donating blood. While such a threat
could chill donation activity, donor dissuasion might be a positive rather than
a negative side-effect. Those most fearful of future litigation will be those
most fearful that their blood is contaminated. These are precisely the people
that modem blood policy seeks to discourage from attempting donation. In
balancing the costs and benefits of donor registration, chilling effects on
donations by persons infected with HIV should be calculated as benefits.
Accordingly, some proponents of donor identification procedures defend the
process as a way of discouraging high-risk persons from making donations." 5
300. Id. at 484.
301. Id. at485-88.
302. Id. at486,488.
303. Selected Recent Court Decisions, Blood Industry: Discovery from Anonymous Donors-
Watson v. Lowcountry Red Cross, 18 AM. J.L. & MED. 280, 281 (1992).
304. See Watson, 974 F.2d 482.
305. Robert K. Jenner, Identifying HI-Infected Blood Donors, TRiAL, June 1989, at 47, 50.
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Prudent policy must consider the predicted magnitude of both positive and
negative chilling effects,3" as well as the possible utility of central registries
discussed in Section IV.E.l. This analysis should entail a number of
considerations, including the degree to which the chilling effect impairs pure
blood donations; the value of the marginal loss of pure blood donations,
considering the adequacy of supply levels; and the degree to which the
chilling effect impairs impure blood donations. The more that persons at high
risk for IV are disproportionately dissuaded from donating by the
maintenance of registries, the more likely that chilling effects will confer a net
benefit rather than a net cost.
Finally, all these considerations must be added to the balancing of
considerations in Sections IV.E.2.a and IV.E.2.b, which generally favored the
implementation of information registries. The resulting analysis suggests that
without evidence that chilling effects will precipitate dangerous blood
shortages, the balance of interests favors policies that encourage donor
registration.
F. Ex Post Facto Procedures to Trace Recipients ofBlood Identified as
High-Risk or Tainted Subsequent to Transfusion
Following transfusion, authorities sometimes suspect or learn that
recipients may have been exposed to HIV. Such a situation can arise as a
result of transfusions received before the development of reliable blood
tests 7 or before the widespread adoption of such tests at different times in
different parts of the world. °8 In addition, technicians may fail to detect HIV
antibodies even when specimens are tested and screened due to laboratory
error" or the window period of serolatency that exists for a brief time
following infection." °
Several procedures can help identify blood recipients whose risk of HIV
infection is discovered only after they have received transfusions. These
procedures include trace-back programs, look-back programs, and archival
306. Positive chilling effects refer to the avoidance of blood donation by persons infected with
HIV. Negative chilling effects refer to the avoidance of blood donation by persons not infected with
IV.
307. Reliable blood tests were not developed and widely implemented before 1985. See supra
note 12.
308. See supra notes 20-21 and accompanying text.
309. See supra notes 262-64 and accompanying text.
310. See supra notes 109-10 and accompanying text.
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searches." ' Under trace-back programs, physicians help blood banks locate
potentially tainted blood by reporting the identities of HIV or AIDS patients
whose only purported exposure to high-risk activity was blood transfusion.3 '2
If appropriate records are kept, blood banks receiving this information can
trace the transfusion to a particular blood unit, which is the "best-guess"
source of the patient's otherwise inexplicable infection.
The blood bank can then apply look-back programs, which identify other
recipients of the same potentially contaminated blood and notify them that
they may have been exposed to HEIV.313 How and when a blood bank should
initiate look-back procedures after tracing contaminated blood may depend
upon situational variables. For instance, if the donee through whom a unit
was traced has never received any transfusions from other sources and reports
no engagement in high-risk behaviors, policymakers must consider whether
the blood bank should immediately use look-back procedures to identify
other donees of blood derived from the same potentially contaminated source
or whether the blood bank should first investigate in order to verify its
suspicions of contamination prior to notification. The trade-off here is
between speed of notification and quality of the information transmitted to
those who may be affected. Whereas early notification gives relevant parties
the most leverage in deciding what measures to take and when to take them, it
can also cause undue alarm should the suspicions of contamination be false.3" 4
Archival searches entail the examination of institutional records to identify
persons who may have been exposed to tainted blood.315 For example,
officials searched the records of the Hospital for Sick Children in Toronto to
find those children who had received open-heart surgery at the hospital
between 1980 and 1985, 316 the period immediately prior to the widespread
311. See M. John Gill et al., Use of Blood Donation History of People with HIV infection to
Identify Recipients at Risk 151 CAN. MED. ASS'N J. 1147, 1148 (1994) (describing trace-back
programs, look-back programs, and archival searches).
312. Id.
313. Id.
314. False suspicions may arise frequently if fearful or embarrassed donees deny participation in
high-risk activities such as homosexual anal intercourse or intravenous drug use. These donees may
seek to avoid the stigma associated in many societies with these practices by falsely attesting that
transfusion is the only high-risk activity in which they have engaged. Such misrepresentation could
result in a proliferation of false alarms associated with trace-back procedures. If so, authorities may
determine that it is prudent to verify suspicions of tainted blood prior to notifying donees through
look-back programs.
315. See id.
316. Id. (citing S.M. King et al., HIV Information Project for Transfision Recipients, 5 PUB.
HEALTH EPIDEMIOLOGY REP. ONT. 25 (1994)).
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availability and adoption of effective lIlV antibody testing. Once identified,
those children were located and examined for symptoms related to HIV.317
Archival searches are a specific variety of look-back program in which
officials peruse records to identify broad classes of persons at risk, such as
those who received blood prior to the development and implementation of
screening procedures.318 Whereas look-back programs often trace specific
individuals who have received blood from very particular, highly suspect
sources, archival searches generally identify larger groups of persons
considered to be at risk.3 19
The similarities between look-back programs and archival searches
suggest that prudent adoption may depend on like considerations, such as (i)
their ability to identify an acceptable number of unwitting donees of tainted
blood, given the costs of implementing the programs, and (ii) the value to
both the identified donees and the public at large of notifying the donees so
they can seek treatment and alter behavior patterns that might otherwise
contribute to the spread of HIV.32 The differences between most look-back
programs and most archival searches suggest that look-back programs are
likely to fare at least somewhat better under a cost-benefit analysis than
archival searches. Because look-back programs generally seek to identify
recipients of specific units of blood believed to have been exposed to LIlV,
they are more likely to identify larger percentages of persons who actually
received contaminated blood than less closely targeted archival searches.32'
Moreover, because they usually focus their search on small, precise groups of
individuals, look-back programs are less expensive than searches that scan
317. Id
318. Seeid.
319. The nomenclature designating some programs as "look-backs" and others as "archival
searches" is imprecise, and the terms are not always consistently used. Further confusion may result
when look-back programs use archival information to locate those persons who received blood from a
single suspected source. Nonetheless, as presently used, look-back programs and archival searches
often differ in terms of the focus of the search.
320. The value of identifying donees so that they can seek treatment and alter their behavior will
be contingent, of course, upon the quality of treatments available for persons with HIV and with AIDS,
as well as the likely effects of knowledge of one's seropositivity on one's propensity to engage in
high-risk activities. As researchers have made significant advances in the treatment of IlV and AIDS
in the middle 1990s, particularly through the development of protease inhibitors, the potential to treat
HIV effectively upon early diagnosis has become more meaningful. For an example of developments
in the treatment of IlV and AIDS in 1995, see supra note 151.
321. This statement is true because the risk of exposure to HIV is much greater if one has been
exposed to a specific unit of blood believed to be tainted than if one has been exposed to a random unit
of blood, even if that random unit was donated before screening procedures were adopted.
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archives for broad classes of potentially vulnerable blood recipients.322
Accordingly, the efficiency and effectiveness of look-back programs are
likely to be superior to the efficiency and effectiveness of archival searches.
G. Encouragement of Autologous Transfusion, Directed Donation, and
Bloodless Surgery
Some transfusion recipients avert the risk of receiving contaminated blood
by arranging to receive autologous transfusion-i.e., transfusion of their own
blood.3' Autologous transfusion is safer than transfusion from anonymous
sources because it exposes the recipient of blood only to contaminants that are
already present in his or her bloodstream.324 While they cannot avoid some
risks, such as the possibility that blood units will be confused and the patient
will receive another person's blood, recipients of autologous transfusions do
avert other risks, such as the possible failure of a blood collection center to
test the blood units to be transfused.
32
Opportunities to receive autologous transfusions are limited by a number
of practical considerations. First, because donors of blood need time to
replenish circulatory blood supplies before undergoing surgery and
autologous transfusion, and because they may need to make several donations
before enough blood is collected for surgical transfusion purposes, lead time
of over a month is usually required to ensure receipt of one's own blood.326
As a result, autologous transfusion is ordinarily limited to elective procedures
that can be scheduled well in advance of surgery.327 Second, a number of
categories of patients are disqualified from autologous transfusion because of
anemia or other conditions that may render the procedure unsafe or
inappropriate. 328 Third, hemophiliacs cannot use autologous products because
322. Tracing records to find those who received transfusions from one unit of blood constitutes a
search on a smaller scale and hence is less expensive than locating all transfusion recipients over a
particular span of time.
323. For a fuller explanation of autologous transfusion and related processes, see Michael
Chapman, The Safest Blood is Your Own, CONSUMERS' REs., Apr. 1994, at 16.
324. Worsnop, supra note 31, at 988 sidebar "Some Donors Give to Themselves."
325. Omissions in the care and consistency of blood testing have resulted in scandals throughout
the era of AIDS. For example, failure to test all collected and processed blood led to a recent blood
scandal in Germany. See Debora MacKenzie, How Safe is Europe's Blood?, NEW SCIENTIST, Jan. 15,
1994, at 12, 12; see also supra note 31.
326. S. Gerald Sandler & Mark A. Popovsky, New Technologiesfor a Safer Blood Supply, TECH.
REv., July 1990, at 23, 26.
327. Id. at 25-26.
328. Id.
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they must receive clotting factors that their own bodies do not produce.329
Detractors have criticized autologous transfusion as inefficient and
expensive for both individuals and society. The patient who donates blood for
autologous transfusion ordinarily pays between $100 and $200 per pint, a
range that exceeds the prices typically charged for non-autologous blood."0
Costs to the individual can be exacerbated further by insurance policies that
exclude coverage of autologous transfusion.33" '
More importantly, the social costs of autologous transfusion are
considerable. Because blood for autologous transfusion is earmarked for
receipt by the donor, it may not be subjected to the rigorous testing of
anonymous blood.332 Accordingly, much of the forty-four percent of
autologous blood that is not used by the donor is discarded333 rather than
redirected to other persons. 34 In itself, this waste is not a compelling
argument against encouraging autologous transfusion. The pool of blood
designated for autologous transfusion is separate from the pool of blood
donated for anonymous transfusion. In most instances, blood donated for
autologous transfusion simply would not have been donated at all but for the
anticipation of the donor's own elective surgery. This means that the volume
of blood donated for autologous transfusion largely augments, rather than
replaces, the non-dedicated blood supply. Accordingly, the practice of
autologous transfusion is unlikely to deplete public blood supplies. Some
have suggested that predepositing one's own blood in anticipation of elective
surgery reduces the demand for blood from the community supply,335
potentially increasing the blood available for nonautologous transfusion.
That autologous transfusion is highly cost-ineffective may be a more
329. See Worsnop, supra note 31, at 994 sidebar "Screening Test Gives Hemophiliacs a Brighter
Future" (observing that the plasma that is the source of blood clotting factors for hemophiliacs comes
from many pooled donations, so that hemophiliacs are exposed by transfusion to thousands of donors
at once).
330. Banking Your Own Blood Not Worth Cost or Effort, TIMES UNION (Albany), Feb. 2, 1996, at
C4, available in Westlaw, TIMESUNION Database.
331. Id.
332. See Worsnop, supra note 31, at 988 cmt. (Some Donors Give to Themselves).
333. Id.
334. Some researchers have begun to investigate opportunities to diminish waste by redirecting
unused autologous blood donations. See, e.g., Jane M. Starkey et al., Markers for Transfusion-
Transmitted Disease in Different Groups of Blood Donors, 262 JAMA 3452 (1989).
335. See Pearl T.C.Y. Toy et al., Predeposited Autologous Blood for Elective Surgery: A National
Multicenter Study, 316 NEW ENG. J. MED. 517, 519 (1987); Roslyn Yomtovian et al., A Blood Drive
Enlisting Past Autologous Donors, MED. LABORATORY OBSERVER, Aug. 1988, at 65.
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compelling argument against the procedure.36 Assessing cost-effectiveness
requires several pieces of information. First, how many new cases of HIV
contamination, hepatitis contamination, and other contaminations are avoided
by autologous transfusion? Second, what is the net benefit of these averted
infections? Finally, what is the cost of processing all blood for autologous
transfusion? The literature in this area suggests that each life-year saved
through preoperative autologous donation is extremely expensive, ranging
anywhere from $200,000 to $2 million.337
Research posits a number of reasons why autologous blood donations are
more expensive than anonymous donations, including the logistical costs
related to scheduling and inventory management, as well as practice-related
costs such as patient counseling.338 Moreover, because the risk of contracting
HIV and hepatitis through an anonymous donation in the United States has
been minimized via the policies previously discussed,339 the numbers of
infections averted by the expensive process of autologous transfusion will be
small. These factors likely contribute to findings that the incremental costs of
autologous blood donation are very high relative to the incremental benefits
associated with reductions in the transmission of disease. 4 Accordingly, until
the cost per life-year saved through autologous transfusion can be reduced,
regulations and policies to encourage autologous blood donation should not
336. Whether encouragement of autologous transfusion is a cost-effective policy differs from
whether an individual will want to incur the costs of predonating his or her own blood in anticipation
of elective surgery. Even if the social costs of autologous transfusion exceed the social benefits, it is
likely that many individuals would still be willing to predonate as an insurance policy against even a
small possibility of contracting HIV.
337. See J.D. Birkmeyer et al., The Cost-Effectiveness of Preoperative Autologous Blood
Donation for Total Hip and Knee Replacement, 33 TRANSFUSION 544, 549 tbl.4 (1993); John D.
Birkmeyer et al., Cost-Effectiveness of Preoperative Autologous Donation in Coronary Artery Bypass
Grafting, 57 ANNALS THORACIC SURGERY 161, 165 tbl.3 (1994).
338. See Cynthia J. Rutherford & Harold S. Kaplan, Autologous Blood Donation-Can We Bank
on It?, 332 NEW ENG. J. MED. 740,741 (1995).
339. See supra notes 71-86 and accompanying text.
340. See generally Jeff Etchason et al., The Cost Effectiveness of Preoperative Autologous Blood
Donations, 332 NEW ENG. J. MED. 719 (1995). It should be remembered, however, that the results of
any cost-benefit analysis incorporate and reflect a researcher's own valuation scheme. Consider, for
example, the valuation of averted infections in terms of medical expenses, lost wages, and pain and
suffering. Whereas determining the value of avoiding medical expenses is relatively objectively
quantifiable, determining the value of avoiding pain and suffering is obviously more troublesome.
Moreover, not all researchers are in agreement regarding the cost-effectiveness of autologous
transfusions. According to some, "[t]he most effective and least costly strategies to reduce HIV
infection transmitted by transfusion of blood and blood products involve decreasing the use of
homologous blood transfusions." Schwartz et al., supra note 123, at 1709.
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be adopted.3
41
Related to autologous transfusion is the practice of directed donation,342 in
which a donor of blood designates the recipient, usually a friend or relative.343
While those who arrange to receive a directed donation presume the process
will reduce the chance of contracting HIV, some blood bankers and
researchers suggest that directed donations may in fact be riskier than
anonymous donations." They reason that people feel pressure to hide high-
341. Should autologous transfusion ever become so marginally effective and cost efficient that it
should be encouraged by sound public policy, a secondary question will arise: whether autologous
transfusion should be made available to all patients anticipating elective surgery. Patients known to be
infected with HIV, for example, may wish to donate their own blood for future transfusion to avoid
exposure to threatening viruses. Autologous transfusion by HIV-infected patients may eliminate or
reduce a number of risks associated with transfusion of anonymously donated blood, including
immunosuppression, viral infection, and activation of HIV replication. See Paul D. Mintz,
Commentary, Participation of HIV-Infected Patients in Autologous Blood Programs, 269 JAMA 2892,
2893 (1993).
Although autologous transfusion can reduce the danger to IHV-positive recipients, risks of error
or inadvertent contamination may be associated with the collection and storage of infected blood. See,
e.g., A Deadly Mistake in a Troubled Hospital: HIV-Contaminated Transfuision Underscores the Need
for Reforms at King, L.A. TIMES, Dec. 21, 1995, at B8 (reporting transfusion of contaminated blood
that had been directed for quarantine). The interests of prospective HIV-infected autologous donors
potentially conflict with the interests of other patients, particularly uninfected autologous donees who
may bear the risk of oversights that could result in their exposure to contaminated blood. Mintz, supra,
at 2893.
As soon as HIV-infected blood enters the supply, it is available for erroneous transfusion.
According to one study done in New York, allogeneic blood is transfused into the wrong patient once
for every 12,000 units of blood. J.V. Linden et al., A Report of 104 Transfusion Errors in New York
State, 32 TRANSFUSION 601, 601, 603 & tbl.3 (1992). The risk of even infrequent infusion of infected
blood into previously uninfected patients raises serious concerns, especially given that over 90% of
those transfused with seropositive blood become infected with HIY themselves as a result. See supra
notes 46-47 and accompanying text.
In calculating the magnitude of these risks, policymakers should consider whether special labeling
and handling provisions for contaminated blood, as well as other administrative provisions, have the
potential to lower misdirected transfusion rates. For example, regulations that require the clear labeling
of seropositive units as "autologous use only" and "biohazard" may be a reasonable means of
attempting to monitor lIV-infected autologous donations. Nonetheless, even if labeling error can be
eliminated, correctly labeled units can still be given to the wrong patient. Because anaesthetized
patients can do nothing to rectify errors in identity, the problem of patient mix-ups is potentially
daunting. See generally W.H. Dzik & S. Devarajan, Should Autologous Blood That Tests Positive for
Infectious Diseases Be Used or Discarded?, 29 TRANSFUSION 743 (1989).
342. Directed donation is also referred to as "recipient-selected transfusion."
343. For more detailed discussion of directed donation, see Margot S. Kruskall & Joel Umlas,
Acquired Immunodeficiency Syndrome and Directed Blood Donations, 123 ARCHIVES SURGERY 23
(1988).
344. See P. Toy et al., Abstract S52, Higher Non-A, Non-B Hepatitis Surrogate Marker Rates in
Designated Donor Units, 28 TRANSFUSION 17S (1988); Harvey M. Sapolsky, AIDS, Blood Banking,
and the Bonds of Community, DAEDALUS, Summer 1989, at 145, 154-55 (noting blood bankers'
concerns regarding the safety of directed donation).
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risk behaviors when approached by friends or relatives requesting a directed
donation.345 Survey data support this concern, reporting that twenty-two
percent of directed donors would consider altering their responses to
questions concerning their health in order to make a directed donation.346
Under these conditions, the voluntary nature of directed donation may be
compromised, yielding a potentially heightened risk of HIV contamination. 37
Proponents of directed blood donations suggest an alternative
hypothesis-that directed donations should be safer than the blood supply at
large. This hypothesis reasons that donors who know their recipients and
agree to direct blood to them will be more concerned about the recipients'
safety than donors who give blood to anonymous donees.348 Under such
reasoning, individuals who know their blood is high-risk will be less likely to
donate to those they know and care about than to those they do not know.349
Other supporters of directed donation have suggested that the pressure to
provide blood without disclosing high-risk behavioral history can be greater
in anonymous donation settings than in the more personal process of
soliciting a directed donation."' One commentator, for example, describes
employer blood drives in which "Blood Captains" are designated to
encourage employee donations.31' As employees frequently move en masse to
donate blood, the expectation that a high-risk donor will divulge his or her
unsuitability to donate may be very unrealistic. 35 2 These observations suggest
that disturbing pressures to lie may exist in regard to both directed and
anonymous donation. 53
Concern that directed donors feel pressured to hide high-risk histories is
exacerbated by negative cost factors. Directed donations require the same
individual processing as autologous blood donations and are subject to the
same degree of waste. The relatively high costs of autologous blood
345. Sapolsky, supra note 344, at 155.
346. See B. Newman, Abstract A86, Directed Donations-A Look at Various Issues, 27
TRANSFUSION 574, 574 (1987).
347. For a very brief discussion of the idea that directed donations are not truly voluntary, see
D.R. Parsons,& D.T. Miller, Abstract A90, A Proposal to Classify Directed Donors as Non-Voluntary,
27 TRANSFUSION 575 (1987).
348. Roberts & Wolkoff, supra note 167, at 175.
349. Id.
350. See Sapolsky, supra note 344, at 154-55.
351. Linda J. Anderson, The AIDS Crisis and Directed Donations, 37 MED. TRIAL TECH. Q. 451,
463 (1991 Annual).
352. Cf id.
353. Id.
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donations are therefore associated with directed donations as well. Because
directed donations are subject to both risk factors and cost factors, their net
social desirability is lower than that of autologous transfusion. Accordingly,
while directed donations should be permitted in the interests of individual free
choice, they should not be supported or encouraged by legal or regulatory
inducements.
An alternative to both autologous transfusion and directed donations is the
adoption of so-called "bloodless" surgery techniques. Bloodless surgery is a
transfusion-free procedure originally developed in response to the objections
of Jehovah's Witnesses to blood transfusion. 4 The process entails recycling
a patient's own blood during an operation through the use of a machine called
a "cell saver."355
While it is more suitable for some forms of surgery than for others,
356
bloodless surgery is quickly gaining support within the medical community.
In early 1996, for example, the Good Samaritan Hospital in Los Angeles
adopted a surgical program featuring bloodless surgery to eliminate
opportunities for the transmission of HIVY Similar programs have been
developed recently by hospitals in Ohio,356 Nevada,359 New Jersey,310 New
York, 61 and Florida.362 As of late 1995, approximately fifty blood centers
around the country offered some form of bloodless surgery.363
According to the coordinator of the Good Samaritan hospital's surgical
program, bloodless surgery not only averts infection opportunities, but also
354. Doctors Meet on Bloodless Surgery, UPI, Oct. 6, 1995, available in LEXIS, News Library,
Cumws File.
355. See Marty Munson, Bloodless Surgery, PREVENTION, Jan. 1996, at 48.
356. The recycling of blood is not suitable for cancer surgery or bowel surgery because the
patient's blood may contain tumor cells or bacteria. Geoffrey Cowley et al., In Search of Safer Blood,
NEWSWEEK, Aug. 10, 1992, at 44, 44. The process is more suitable for orthopedic and cardiovascular
surgery. See id.
357. "Bloodless" Surgery Going Mainstream at L.A. Hospital, MOD. HEALTH CARE, Jan. 29,
1996, at 52.
358. Joan Whitely, Options Cut Blood Loss in Surgery, LAS VEGAS REv.-J., Jan. 16, 1996, at 1E
(noting the bloodless surgery program at St. Vincent Charity Hospital in Cleveland, Ohio), available in
1996 WL 2333213.
359. Id.
360. Bob Groves, Bloodless Surgery Gaining Wider Use: Englewood Hospital to Offer Option,
REcORD (N.N.J.), Sept. 19, 1994, available in 1994 WL 7770790.
361. Randi Glatzer, Science Meets Religion: Doctor Tailors Treatment for Jehovah s Witnesses by
Performing Surgery Without Transfusions, NEWSDAY, Feb. 20, 1994, available in 1994 WL 7425073.
362. Sandra Jacobs, "Bloodless Surgery" Steps up to the Operating Table, MIAMI HERALD, Feb.
22, 1995, at 1E, available in Westlaw, MIA-HRLD Database.
363. See Whitely, supra note 358; Doctors Meet on Bloodless Surgery, supra note 354.
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hastens patient recovery and reduces medical costs.3" These observations
suggest that bloodless surgery is an inexpensive, effective way to avert
contamination by reducing reliance on blood transfusions. Public financial
support for the implementation of cost-efficient bloodless surgery programs
compares favorably with more expensive and dubiously effective policies,
such as the financing of autologous blood donation programs.
V. CONCLUSION
This Article has examined rule-based methods of promoting the safety of
blood supplies in the form of laws, regulations, and public policies. All the
observations and recommendations in the preceding section incorporate the
fundamental economic axiom that decisions bear opportunity costs.365 For
some policies, the high costs of saving incremental life-years cannot be
justified, given the alternative social benefits of more efficient, effective
employment of funds.
Given these assumptions, the discussion in Section IV yields several
recommendations and observations. In general, the federal government is
justified in requiring testing of donated blood and the rejection of HIV-
contaminated donations. The present method-ELISA with Western Blot
confirmation-is a highly effective screening process, the cost of which is far
exceeded by its benefits. Conversely, supplemental antigen testing, soon to be
mandated by the FDA, is exorbitantly expensive. This requirement cannot be
justified under any reasonable cost-benefit analysis and should be abolished.
When a blood donation tests positive, the donor should be informed of his
or her exposure to HIV. This policy requires the implementation of reliable
safeguards that ensure confidentiality and prohibit discrimination against
persons infected with HIV. Convenient and affordable testing sites must be
provided to discourage the use of blood collection centers to learn one's
serostatus.
Because evidence suggests that sold blood is significantly more likely to
be contaminated than donated blood, the sale of blood should be strictly
prohibited. Should this measure precipitate severe blood shortages in some
locations, officials must investigate methods to increase the blood supply
364. See "Bloodless" Surgery Going Mainstream in L.A. Hospital, supra note 357.
365. For further explanation and discussion of the inevitability of opportunity costs in
decisionmaking, see E.V. BOWDEN, ECONOMICS: THE SCIENCE OF COMMON SENSE 32 (5th abr. ed.
1986).
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other than payment for blood. Such methods might include increasing
budgets for the promotion of gratuitous donations and marketing altruistic
reasons for giving blood. The question of cash payments for blood may need
revisiting should future technological and procedural improvements in blood
testing eliminate the possibility of contaminated blood entering the blood
supply.
Predonation questioning and exclusion procedures are effective tools that
can help to minimize the entry of contaminated blood into public supplies.
Behavioral classifications that are associated with known means of HIV
transmission are more effective categories for exclusion than status-based
classifications, which incorporate the error that is inevitably associated with
all forms of stereotyping. The greater the error, the more good blood is
needlessly discarded, potentially resulting in blood supply shortages.
Moreover, as HIV and AIDS spread throughout the population, status-based
exclusions, such as the exclusion of gay men, become increasingly irrational.
More useful behavior-linked classifications must continually be reassessed, as
the means of HIV transmission and our knowledge of those means continue
to evolve. Finally, federal and state agencies should consider encouraging or
mandating the use of computerized questionnaire methods to maximize
privacy and minimize respondent misrepresentations.
The regulations that govern and monitor information transmission,
operating procedures, and the maintenance of blood supplies play an
important role in blood supply safety. Labeling requirements mandating
uniformity in the development and handling of blood labels discourage errors
in interpretation by providing consistent information across states and
regions. As computerization becomes increasingly prevalent, the FDA should
consider promulgating regulations mandating blood collection centers and
blood banks to adopt a uniform computerized coding system. A uniform
system can prevent mix-ups and increase consistency in the designation and
interpretation of labels.
Federal preemption of state regulation of blood centers' operating
procedures and monitoring mechanisms is long overdue. Given the
nationalization of the market for blood, public health would be served best by
one set of carefully considered rules and standards applied consistently to all
aspects of U.S. blood regulation.
The development and maintenance of blood registries play an important
role in locating recipients of blood that is identified after transfusion as
potentially contaminated. The ability to identify persons who may have
received tainted blood bears a number of benefits: it allows those infected to
19961
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seek treatment; it enables officials to notify those infected not to donate
blood; and it ensures the public that the blood industry is committed to acting
responsibly and accountably at all stages of blood collection and distribution.
While registered donor information is subject to abuse, such as discrimination
and breach of privacy, lawmakers and administrators can implement both
regulatory and procedural safeguards to protect donors while preserving vital
sources of information.
Finally, three alternatives to the transfusion of blood from anonymous
donors have some potential to reduce the risk of HIV transmission-these are
autologous transfusion, directed donation, and bloodless surgery. Although an
autologous transfusion can reduce a patient's chances of contracting AIDS,
most studies indicate that the social cost of the procedure exceeds its social
benefits. Accordingly, while autologous transfusion should remain an option
for patients, it should not be encouraged as a policy through the development
of subsidies or other incentives. Because directed donation shares the cost
disadvantages of autologous transfusion and may also encourage donors to lie
about high-risk behaviors, public policy should likewise permit but not
encourage the practice. A more promising alternative to transfusions from the
public blood supply is bloodless surgery, a procedure that confers many
benefits while exacting few costs. Tax incentives, subsidies, or other
governmental dispensations encouraging hospitals to develop bloodless
surgery programs can hasten patient recovery and reduce HIV transmissions
and medical expenditures.
The foregoing analysis has addressed exclusively those strategies for
reducing the incidence of transfusion-based HIV infection that are widely
considered by lawmakers and policymakers to be promising in the immediate
future. The list of possibilities is ever changing, and innovative or
controversial technologies require an ongoing assessment of continually
emerging policy candidates and their impact on the portfolio of techniques
that protect the public blood supply.366
366. Controversy exists, for instance, regarding the process of solvent-detergent treatment of
frozen plasma, adopted in some European countries to reduce the risk of transmitting HIV and other
viruses. AuBuchon & Birkmeyer, supra note 118, at 1210. The costs and benefits of this treatment
have been called into question by researchers in the United States. See id. at 1212-13.
[VOL. 74:913
https://openscholarship.wustl.edu/law_lawreview/vol74/iss4/2
